

## Clinical Trial Protocol

<b>Document Number:</b>		<b>c26556329-02</b>
<b>EudraCT No.</b>	2019-001570-28	
<b>BI Trial No.</b>	1405-0009	
<b>BI Investigational Medicinal Product</b>	BI 1323495	
<b>Title</b>	Relative bioavailability of a single oral dose of BI 1323495 when administered alone or in combination with multiple oral doses of itraconazole in healthy male subjects (an open-label, one-way crossover study)	
<b>Lay Title</b>	A study in healthy men to test how itraconazole influences the amount of BI 1323495 in the blood	
<b>Clinical Phase</b>	I	
<b>Clinical Trial Leader</b>	Phone: Fax:	
<b>Principal Investigator</b>	Phone: Fax:	
<b>Status</b>	Final Protocol (Revised Protocol (based on global amendment 1))	
<b>Version and Date</b>	Version: 2.0	Date: 18 June 2019
<b>Page 1 of 62</b>		
<b>Proprietary confidential information</b>		
<b>© 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies. All rights reserved.</b> This document may not - in full or in part - be passed on, reproduced, published or otherwise used without prior written permission		

## **CLINICAL TRIAL PROTOCOL SYNOPSIS**

<b>Company name</b>	Boehringer Ingelheim
<b>Protocol date</b>	18 June 2019
<b>Revision date</b>	Not applicable
<b>BI trial number</b>	1405-0009
<b>Title of trial</b>	Relative bioavailability of a single oral dose of BI 1323495 when administered alone or in combination with multiple oral doses of itraconazole in healthy male subjects (an open-label, one-way crossover study)
<b>Principal Investigator</b>	
<b>Trial site</b>	
<b>Clinical phase</b>	I
<b>Trial rationale</b>	Based on <i>in vitro</i> data, CYP3A4 and P-gp are involved in metabolism and transport of BI 1323495, respectively. It is therefore necessary to explore the relative bioavailability of BI 1323495 in plasma when given alone versus when given together with a strong CYP3A4 and P-gp inhibitor.
<b>Trial objective</b>	To investigate the relative bioavailability of a single oral dose of BI 1323495 when given alone (treatment R) or in combination with itraconazole (treatment T).
<b>Trial design</b>	Open-label, two-treatment, two-period, one-way crossover design
<b>Trial endpoints</b>	Primary endpoints: AUC <sub>0-tz</sub> and C <sub>max</sub> of BI 1323495 Secondary endpoints: AUC <sub>0-∞</sub> of BI 1323495
<b>Number of subjects</b>	
<b>total entered</b>	14
<b>each treatment</b>	14
<b>Diagnosis</b>	Not applicable
<b>Main criteria for inclusion</b>	Healthy male subjects, age of 18 to 50 years (inclusive), body mass index (BMI) of 18.5 to 29.9 kg/m <sup>2</sup> (inclusive),
<b>Test product 1</b>	BI 1323495 tablet formulation
<b>dose</b>	
<b>mode of admin.</b>	Oral with 240 mL of water after an overnight fast of at least 10 h

Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies

<b>Test product 2</b>	Itraconazole oral solution (Sempera® Liquid 10 mg/mL)
<b>dose</b>	200 mg q.d.
<b>mode of admin.</b>	Oral with 240 mL of water after an overnight fast of at least 9 h
<b>Duration of treatment</b>	<p><u>Treatment R (BI 1323495 alone):</u> Single dose of BI 1323495 (Day 1)</p> <p><u>Treatment T (itraconazole + BI 1323495):</u> 10 days of itraconazole treatment (200 mg itraconazole once daily from Day -3 to Day 7) combined with a single dose of BI 1323495 on the fourth day of the itraconazole treatment (Day 1, 1 h after the itraconazole administration)</p> <p><u>Wash-out period:</u> Administrations of BI 1323495 will be separated by a wash-out phase of at least 7 days</p>
<b>Statistical methods</b>	Relative bioavailability will be estimated by the ratios of the geometric means (test/reference) for the primary and secondary endpoints. Additionally, their two-sided 90% confidence intervals (CIs) will be provided. This method corresponds to the two one-sided t-test procedure, each at a 5% significance level. Since the main focus is on estimation and not testing, a formal hypothesis test and associated acceptance range are not specified. The statistical model will be an analysis of variance (ANOVA) on the logarithmic scale including effects for 'subject' and 'treatment'. CIs will be calculated based on the residual error from the ANOVA.  Descriptive statistics will be calculated for all endpoints.

## FLOW CHART

Period	Visit	Day	Planned time (relative to drug administration) [h:min]	Approximate clock time of actual day [h:min]	Event and comment	Safety laboratory <sup>5</sup>	PK blood, BI 1323495	PK blood, Itraconazole	12-lead ECG	Vital signs (BP, PR)	Questioning for AEs and concomitant therapy <sup>7</sup>
SCR	1	-21 to -3			Screening (SCR) <sup>1</sup>	x <sup>A</sup>			x	x	
Period 1/ Treatment R (BI 1323495 alone) <sup>8</sup>			2	-3 to -1	-75:00 06:00	Ambulatory visit	x <sup>B</sup>				x
			1	-3:00 06:00	Admission to trial site <sup>2</sup>	x <sup>2,3</sup>	x <sup>2</sup>	x <sup>2</sup>	x <sup>2</sup>	x <sup>2</sup>	x <sup>2</sup>
					0:00 09:00 BI 1323495 administration						
					0:20 09:20		x				
					0:40 09:40		x				
					1:00 10:00		x				
					2:00 11:00 240 mL fluid intake		x				
					3:00 12:00		x				
					4:00 13:00 240 mL fluid intake, thereafter lunch <sup>4</sup>	x			x	x	x
					5:00 14:00		x				
					6:00 15:00		x				
					7:00 16:00 Snack (voluntary) <sup>4</sup>	x					
					8:00 17:00		x				
					10:00 19:00 Dinner <sup>4</sup>		x				
			2	12:00 24:00 09:00	12:00 21:00		x				x
					24:00 09:00 Breakfast (voluntary) <sup>4</sup> , discharge from trial site	x <sup>B</sup>	x		x	x	x
					34:00 19:00 Ambulatory visit		x				x
					47:00 08:00 Ambulatory visit		x				x
			3	71:00 08:00	Ambulatory visit	x <sup>B</sup>	x				x
			4	95:00 08:00	Ambulatory visit		x				x

1. Subject must be informed and written informed consent obtained prior to starting any screening procedures. Screening procedures include physical examination, check of vital signs, ECG, safety laboratory (including drug screening), demographics (including determination of body height and weight, smoking status and alcohol history), relevant medical history, concomitant therapy and review of inclusion/exclusion criteria.
2. The time is approximate; the procedure is to be performed and completed within the 3 h prior to drug administration.
3. Urine drug screening and alcohol breath test
4. If several actions are indicated at the same time, the intake of meals will be the last action.
5. Letters A, B, C, and D define different sets of safety laboratory examinations (for details refer to Section 5.2.3)
6. At the end of trial visit the EoTrial examination includes physical examination, vital signs, ECG, safety laboratory, recording of AEs and concomitant therapies.
7. AEs and concomitant therapies will be recorded throughout the trial, but will be specifically asked for at the times indicated in the Flow Chart above.
8. Administration of BI 1323495 in treatment R and T will be separated by at least 7 days.
9. Blood collection takes place at the indicated times. Itraconazole will be administered immediately thereafter.

Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies

FLOW CHART (cont'd)

Period	Visit	Day	Planned time (relative to drug administration) [h:min]	Approximate clock time of actual day [h:min]	Event and comment	Safety laboratory <sup>5</sup>	PK <sub>blood</sub> , BI 1323495	PK <sub>blood</sub> , Itraconazole	12-lead ECG	Vital signs (BP, PR)	Questioning for AEs and concomitant therapy <sup>7</sup>
Period 2/ Treatment T (BI 1323495 + itraconazole) <sup>8</sup>	3	-3	-73:00	08:00	Ambulatory visit, itraconazole administration	x <sup>B,2,3</sup>					x <sup>2</sup>
		-2	-49:00	08:00	Ambulatory visit, itraconazole administration						x <sup>2</sup>
		-1	-25:00	08:00	Ambulatory visit, itraconazole administration	x <sup>C,2</sup>		x <sup>9</sup>			x <sup>2</sup>
		1	-3:00	06:00	Admission to trial site <sup>2</sup>		x <sup>2</sup>		x <sup>2</sup>	x <sup>2</sup>	x <sup>2</sup>
			-1:00	08:00	Itraconazole administration			x <sup>9</sup>			
			0:00	09:00	BI 1323495 administration						
			0:20	09:20			x				
			0:40	09:40			x				
			1:00	10:00			x				
			2:00	11:00	240 mL fluid intake		x				
			3:00	12:00			x				
			4:00	13:00	240 mL fluid intake, thereafter lunch <sup>4</sup>		x		x	x	x
			5:00	14:00			x				
			6:00	15:00			x				
			7:00	16:00	Snack (voluntary) <sup>4</sup>		x				
			8:00	17:00			x				
			10:00	19:00	Dinner <sup>4</sup>		x				
			12:00	21:00			x				x
		2	23:00	08:00	Itraconazole administration	x <sup>B,2</sup>					x
			24:00	09:00	Breakfast (voluntary) <sup>4</sup>		x		x	x	x
			28:00	13:00	Lunch (voluntary)						
			31:00	16:00	Snack (voluntary)						
			34:00	19:00	Discharge from trial site		x				x
		3	47:00	08:00	Ambulatory visit, itraconazole administration		x <sup>9</sup>	x <sup>9</sup>			x
		4	71:00	08:00	Ambulatory visit, itraconazole administration	x <sup>C,2</sup>	x <sup>9</sup>				x
		5	95:00	08:00	Ambulatory visit, itraconazole administration		x <sup>9</sup>				x
		6	119:00	08:00	Ambulatory visit, itraconazole administration	x <sup>C,2</sup>	x <sup>9</sup>				x
		7	143:00	08:00	Ambulatory visit, itraconazole administration		x <sup>9</sup>	x <sup>9</sup>			x
		8	167:00	08:00	Ambulatory visit	x <sup>B</sup>	x	x			x
FU	4	16 to 23			End of trial (EoTrial) examination <sup>6</sup>	x <sup>D</sup>			x	x	x

1. Subject must be informed and written informed consent obtained prior to starting any screening procedures. Screening procedures include physical examination, check of vital signs, ECG, safety laboratory (including drug screening), demographics (including determination of body height and weight, smoking status and alcohol history), relevant medical history, concomitant therapy and review of inclusion/exclusion criteria.
2. The time is approximate; the procedure is to be performed and completed within the 3 h prior to drug administration.
3. Urine drug screening and alcohol breath test
4. If several actions are indicated at the same time, the intake of meals will be the last action.
5. Letters A, B, C, and D define different sets of safety laboratory examinations (for details refer to Section 5.2.3)
6. At the end of trial visit the EoTrial examination includes physical examination, vital signs, ECG, safety laboratory, recording of AEs and concomitant therapies.
7. AEs and concomitant therapies will be recorded throughout the trial, but will be specifically asked for at the times indicated in the Flow Chart above.
8. Administration of BI 1323495 in treatment R and T will be separated by at least 7 days.
9. Blood collection takes place at the indicated times. Itraconazole will be administered immediately thereafter.

## TABLE OF CONTENTS

<b>TITLE PAGE .....</b>	<b>1</b>
<b>CLINICAL TRIAL PROTOCOL SYNOPSIS .....</b>	<b>2</b>
<b>FLOW CHART .....</b>	<b>4</b>
<b>TABLE OF CONTENTS .....</b>	<b>6</b>
<b>ABBREVIATIONS .....</b>	<b>10</b>
<b>1. INTRODUCTION.....</b>	<b>13</b>
1.1 MEDICAL BACKGROUND.....	13
1.2 DRUG PROFILE .....	13
1.2.1 BI 1323495 .....	13
1.2.2 Itraconazole .....	15
1.2.3 Residual Effect Period .....	15
1.3 RATIONALE FOR PERFORMING THE TRIAL.....	16
1.4 BENEFIT - RISK ASSESSMENT .....	16
1.4.1 Procedure-related risks .....	16
1.4.2 Drug-related risks and safety measures.....	16
1.4.2.1 Drug-induced liver injury .....	16
1.4.2.2 BI 1323495.....	17
1.4.2.3 Itraconazole.....	18
1.4.2.4 Potential interaction between itraconazole and BI 1323495....	19
1.4.2.5 Safety Measures .....	19
1.4.2.6 Benefit –Risk Assessment Summary .....	19
<b>2. TRIAL OBJECTIVES AND ENDPOINTS.....</b>	<b>20</b>
2.1 MAIN OBJECTIVES, PRIMARY AND SECONDARY ENDPOINTS .....	20
2.1.1 Main objectives.....	20
2.1.2 Primary endpoints .....	20
2.1.3 Secondary endpoint .....	20
<b>3. DESCRIPTION OF DESIGN AND TRIAL POPULATION.....</b>	<b>22</b>
3.1 OVERALL TRIAL DESIGN AND PLAN .....	22
3.2 DISCUSSION OF TRIAL DESIGN, INCLUDING THE CHOICE OF CONTROL GROUPS.....	22
3.3 SELECTION OF TRIAL POPULATION .....	23
3.3.1 Main diagnosis for trial entry .....	23

Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies

3.3.2 Inclusion criteria .....	23
3.3.3 Exclusion criteria .....	23
3.3.4 Withdrawal of subjects from treatment or assessments .....	25
3.3.4.1 Discontinuation of trial treatment .....	25
3.3.4.2 Withdrawal of consent to trial participation .....	26
3.3.4.3 Discontinuation of the trial by the sponsor .....	26
3.3.5 Replacement of subjects .....	26
<b>4. TREATMENTS.....</b>	<b>27</b>
<b>4.1 INVESTIGATIONAL TREATMENTS .....</b>	<b>27</b>
4.1.1 Identity of the Investigational Medicinal Products .....	27
4.1.2 Selection of doses in the trial.....	28
4.1.3 Method of assigning subjects to treatment groups .....	28
4.1.4 Drug assignment and administration of doses for each subject .....	29
4.1.5 Blinding and procedures for unblinding .....	29
4.1.6 Packaging, labelling, and re-supply .....	30
4.1.7 Storage conditions.....	30
4.1.8 Drug accountability .....	30
<b>4.2 OTHER TREATMENTS, EMERGENCY PROCEDURES, RESTRICTIONS .....</b>	<b>31</b>
4.2.1 Other treatments and emergency procedures.....	31
4.2.2 Restrictions .....	31
4.2.2.1 Restrictions regarding concomitant treatment .....	31
4.2.2.2 Restrictions on diet and life style.....	31
<b>4.3 TREATMENT COMPLIANCE .....</b>	<b>32</b>
<b>5. ASSESSMENTS .....</b>	<b>33</b>
<b>5.1 ASSESSMENT OF EFFICACY .....</b>	<b>33</b>
<b>5.2 ASSESSMENT OF SAFETY .....</b>	<b>33</b>
5.2.1 Physical examination .....	33
5.2.2 Vital signs.....	33
5.2.3 Safety laboratory parameters .....	33
5.2.4 Electrocardiogram .....	36
5.2.5 Other safety parameters.....	36
5.2.6 Assessment of adverse events.....	36
5.2.6.1 Definitions of adverse events.....	36
5.2.6.1.1 Adverse event .....	36
5.2.6.1.2 Serious adverse event .....	37
5.2.6.1.3 AEs considered 'Always Serious' .....	37
5.2.6.1.4 Adverse events of special interest .....	38
5.2.6.1.5 Intensity (severity) of AEs.....	38
5.2.6.1.6 Causal relationship of AEs .....	38
5.2.6.2 Adverse event collection and reporting .....	39

Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies

5.2.6.2.1	AE collection .....	39
5.2.6.2.2	AE reporting to the sponsor and timelines .....	40
5.2.6.2.3	Information required.....	40
5.2.6.2.4	Pregnancy .....	40
<b>5.3</b>	<b>DRUG CONCENTRATION MEASUREMENTS AND PHARMACOKINETICS .....</b>	<b>41</b>
5.3.1	Assessment of pharmacokinetics .....	41
5.3.2	Methods of sample collection .....	41
5.3.2.1	Blood sampling for pharmacokinetic analysis of BI 1323495.	41
5.3.2.2	Blood sampling for pharmacokinetic analysis of itraconazole	41
5.3.3	Analytical determinations .....	42
5.3.3.1	Analytical determination of analyte plasma concentration.....	42
5.3.3.2	Further use of plasma samples .....	42
<b>5.4</b>	<b>BIOBANKING .....</b>	<b>42</b>
<b>5.6</b>	<b>APPROPRIATENESS OF MEASUREMENTS .....</b>	<b>43</b>
<b>6.</b>	<b>INVESTIGATIONAL PLAN.....</b>	<b>44</b>
6.1	VISIT SCHEDULE.....	44
6.2	DETAILS OF TRIAL PROCEDURES AT SELECTED VISITS .....	44
6.2.1	Screening period.....	44
6.2.2	Treatment periods.....	44
6.2.3	Follow-up period and trial completion .....	45
<b>7.</b>	<b>STATISTICAL METHODS AND DETERMINATION OF SAMPLE SIZE .....</b>	<b>46</b>
7.1	STATISTICAL DESIGN – MODEL .....	46
7.2	NULL AND ALTERNATIVE HYPOTHESES .....	46
7.3	PLANNED ANALYSES.....	46
7.3.1	Primary endpoint analyses.....	47
7.3.2	Secondary endpoint analyses .....	48
7.3.4	Safety analyses.....	49
7.4	INTERIM ANALYSES .....	49
7.5	HANDLING OF MISSING DATA .....	50
7.5.1	Safety.....	50
7.5.2	Pharmacokinetics .....	50
7.6	RANDOMISATION .....	50
7.7	DETERMINATION OF SAMPLE SIZE .....	50

Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies

<b>8. INFORMED CONSENT, TRIAL RECORDS, DATA PROTECTION, PUBLICATION POLICY, AND ADMINISTRATIVE STRUCTURE .....</b>	<b>52</b>
8.1 TRIAL APPROVAL, SUBJECT INFORMATION, INFORMED CONSENT .....	52
8.2 DATA QUALITY ASSURANCE .....	53
8.3 RECORDS .....	53
8.3.1 Source documents .....	53
8.3.2 Direct access to source data and documents.....	54
8.3.3 Storage period of records .....	54
8.4 EXPEDITED REPORTING OF ADVERSE EVENTS .....	55
8.5 STATEMENT OF CONFIDENTIALITY AND SUBJECT PRIVACY.....	55
8.5.1 Collection, storage and future use of biological samples and corresponding data .....	55
8.6 TRIAL MILESTONES .....	55
8.7 ADMINISTRATIVE STRUCTURE OF THE TRIAL .....	56
<b>9. REFERENCES .....</b>	<b>58</b>
9.1 PUBLISHED REFERENCES.....	58
9.2 UNPUBLISHED REFERENCES.....	60
<b>10. APPENDICES .....</b>	<b>61</b>
<b>11. DESCRIPTION OF GLOBAL AMENDMENT(S) .....</b>	<b>62</b>
11.1 GLOBAL AMENDMENT 1 .....	62

## **ABBREVIATIONS**

ADME	Absorption, distribution, metabolism, and excretion
AE	Adverse event
AESI	Adverse events of special interest
ANOVA	Analysis of variance
AUC <sub>0-∞</sub>	Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity
AUC <sub>0-tz</sub>	Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point
AUC <sub>0-24</sub>	Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to 24 hours after drug administration
BI	Boehringer Ingelheim
BMI	Body mass index (weight divided by height squared)
BP	Blood pressure
CA	Competent authority
CI	Confidence interval
C <sub>max</sub>	Maximum measured concentration of the analyte in plasma
COPD	Chronic obstructive pulmonary disease
CRF	Case Report Form, paper or electronic (sometimes referred to as 'eCRF')
CTP	Clinical trial protocol
CTR	Clinical trial report
CYP	Cytochrome P450
DILI	Drug induced liver injury
ECG	Electrocardiogram
eCRF	Electronic case report form
ED <sub>50</sub>	Effective dose at 50% reduction
eDC	Electronic data capture
EDTA	Ethylenediaminetetraacetic acid
EM	Extensive metabolizer
EoTrial	End of trial
EudraCT	European Clinical Trials Database
FU	Follow-up
GCP	Good Clinical Practice

Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies

gCV	Geometric coefficient of variation
gMean	Geometric mean
HPC	Human Pharmacology Centre
HR	Heart rate
IB	Investigator's brochure
IC <sub>50</sub>	Half-maximal inhibitory concentration
IEC	Independent Ethics Committee
IPD	Important protocol deviation
IRB	Institutional Review Board
ISF	Investigator site file
LC-MS/MS	Liquid chromatography with tandem mass spectrometry
MDA	Methylenedioxymphetamine
MDMA	Methylenedioxymethamphetamine
MedDRA	Medical Dictionary for Regulatory Activities
NOAEL	No observed adverse effect level
P-gp	P-glycoprotein
PK	Pharmacokinetic(s)
PKS	Pharmacokinetic set
PP	Polypropylene
PR	Pulse rate
QT	Time between start of the Q-wave and the end of the T-wave in an electrocardiogram
QTc	QT interval corrected for heart rate using the method of Fridericia (QTcF) or Bazett (QTcB)
R	Reference treatment
REP	Residual effect period
SAE	Serious adverse event
SCR	Screening
SmPC	Summary of Product Characteristics
SOP	Standard operating procedure
SRD	Single-rising dose
T	Test product or treatment
t <sub>max</sub>	Time from (last) dosing to the maximum measured concentration of the analyte in plasma
TS	Treated set

Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies

$t_z$  Time of last measurable concentration of the analyte in plasma

TSAP Trial statistical analysis plan

ULN Upper limit of normal

XTC Ecstasy

## **1. INTRODUCTION**

This trial will be performed to investigate the relative bioavailability of BI 1323495 in plasma when given alone compared to when given together with the CYP3A and P-glycoprotein inhibitor itraconazole.

### **1.1 MEDICAL BACKGROUND**

### **1.2 DRUG PROFILE**

#### **1.2.1 BI 1323495**

For a detailed description of the BI 1323495 profile, please refer to the current Investigator's Brochure (IB) ([c21238478](#)).

At the time of preparing this trial protocol, two Phase I studies with administration of BI 1323495 to healthy male volunteers have been completed, trial 1405-0001 (first-in-man trial, in reporting phase) and study 1405-0007 (relative BA/food effect, in evaluation phase).

In the single rising dose (SRD) trial 1405-0001, single-dose treatment with up to 600 mg BI 1323495 or placebo was safe and well tolerated. There was no relationship between the occurrence of AEs and dose.

For details on safety and tolerability as well as on pharmacokinetics and biomarker data of the SRD trial refer to the IB ([c21238478](#)).

Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies

The clinical part of the [food effect trial 1405-0007](#), a randomised 2-way crossover study to compare the relative bioavailability of a single dose of 100 mg BI 1323495 (50 mg tablet) administered in the fasted state versus fed state (high-fat) conditions, has been completed and data are currently under evaluation.

### 1.2.2 Itraconazole

Absorption of itraconazole solution is fast with maximum plasma concentration being reached within 2.5 h after oral administration in fasting condition. Bioavailability of itraconazole liquid increases by 30% when given under fasting condition compared to administration together with food ([R18-2644](#)). Mean peak plasma concentrations were 547.7 ng/mL after a single dose of 200 mg itraconazole solution (fasting) and 1965 ng/mL after 15 days of daily treatment with 200 mg itraconazole solution (fasting). Pharmacokinetics of itraconazole is non-linear. The half-life of itraconazole after multiple doses of 200 mg once daily with solution formulation was about 40 h ([R17-3742](#)).

In the liver, itraconazole is metabolised extensively to more than 30 metabolites ([R17-3743](#)). Its main metabolite, OH-itraconazole, accounts for about twice the concentration of plasma itraconazole at trough. It has been shown *in vitro* that CYP3A4 is mainly responsible for the formation of this metabolite [R18-2644]. FDA classifies itraconazole as strong index inhibitor of CYP3A and as inhibitor of P-glycoprotein (P-gp) ([R18-0241](#)). However, not only itraconazole contributes to the *in vivo* inhibition of CYP3A observed after itraconazole administration but also three of its metabolites (OH-itraconazole, keto-itraconazole, and N-desalkyl-itraconazole) ([R10-1102](#)).

For a more detailed description of itraconazole, please refer to the German Summary of Product Characteristics (SmPC) for Sempera® Liquid 10 mg/ml [[R18-2644](#)] and the UK SmPC for Sporanox® 10 mg/ml Oral Solution ([R18-2643](#)).

### 1.2.3 Residual Effect Period

The Residual Effect Period (REP, i.e., the period after the last dose with measurable drug levels and/or pharmacodynamic effects still likely to be present) of BI 1323495 is approximately 7 days.

When given together with itraconazole (Treatment T), it is expected that plasma exposure of BI 1323495 could be increased (albeit within the exposures explored in the clinical trial 1405-0001), and the time of relevant plasma exposure could be prolonged. This might result in a prolonged period in which adverse effects could potentially occur.

For the use of itraconazole in Treatment T, the REP is defined as 9 days after last administration of itraconazole on Day 7 in Period 2.

## **1.3 RATIONALE FOR PERFORMING THE TRIAL**

in this trial, the focus is on the DDI victim potential of BI 1323495 with regard to CYP3A4 and P-gp inhibition as this may lead to clinically relevant increases in exposures with potential impact on patient safety.

Itraconazole is chosen for this trial as perpetrator drug, as this drug is recommended as strong inhibitor of CYP3A by EMA ([P15-06991](#)), as strong index inhibitor of CYP3A by FDA ([R18-0241](#)), and as strong inhibitor of CYP3A by PMDA ([P15-06298](#)) and it is an inhibitor of P-gp ([R18-0241](#)). Moreover, safety and tolerability of itraconazole were acceptable in previous drug-drug interaction trials ([c02336088](#), [c03355329](#), [c08928447](#)).

## **1.4 BENEFIT - RISK ASSESSMENT**

Participation in this clinical trial is without any (therapeutic) benefit for healthy subjects. Their participation, however, is of major importance for the development of a new orally available drug, which might improve the therapy in patients with COPD and emphysema. Subjects are exposed to risks of study procedures and risks related to the exposure to the trial medication.

### **1.4.1 Procedure-related risks**

The use of an indwelling venous catheter or venepuncture for e.g. blood sampling may result in mild bruising, and in rare cases, in transient inflammation of the wall of the vein, or nerve injury, potentially resulting in paraesthesia, reduced sensibility, and/or pain for an indefinite period, as well as in feeling of lightheadedness or in syncope.

The total volume of blood withdrawn per subject during the entire study will not exceed the volume of a normal blood donation (500 mL). No health-related risk to healthy subjects is expected from withdrawal of this volume of blood.

### **1.4.2 Drug-related risks and safety measures**

#### **1.4.2.1 Drug-induced liver injury**

Although rare, a potential for drug-induced liver injury (DILI) is under constant surveillance by sponsors and regulators. Therefore, this trial requires timely detection, evaluation, and follow-up of laboratory alterations in selected liver laboratory parameters to ensure subjects' safety; see also Section [5.2.6.1.4](#), adverse events of special interest.

Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies

1.4.2.2 BI 1323495

In the SRD and food effect trial, single dose administration of BI 1323495 up to 600 mg was well tolerated, with no clinically relevant changes in safety lab, ECG, and vital signs observed (ref. Section [1.2.1](#)).

As with all drugs, the potential for hypersensitivity and allergic reactions has to be taken into consideration when BI 1323495 is administered.

#### 1.4.2.3 Itraconazole

In this trial itraconazole will be used in a standard clinical dose of 200 mg once daily for 10 days. Multiple dosing of 200 mg itraconazole up to 15 days was of acceptable tolerability in healthy subjects ([c02336088](#), [c03355329](#), [c08928447](#), [R17-3742](#)).

For a detailed description of the potential risks of itraconazole treatment, please refer to the German Summary of Product Characteristics (SmPC) for Sempera® Liquid 10 mg/ml ([R18-2644](#)).

In order to address the risk of hepatotoxicity, only subjects with normal liver enzyme values will be included into the study. Safety laboratory parameters will be monitored closely. An individual subject will be removed from the trial if the subject shows an elevation of AST and/or ALT  $\geq 3$ -fold ULN combined with an elevation of total bilirubin  $\geq 2$ -fold ULN (measured in the same blood sample, see Section [3.3.4.1](#)).

Further, most of the reported cases of serious hepatotoxicity during itraconazole treatment occurred in patients that suffered from concomitant liver diseases, had other significant diseases, or took concomitant hepatotoxic drugs. Subjects with liver diseases or a medical history of drug-induced liver failure are excluded from trial participation.

Itraconazole has shown a dose-related increase in maternal toxicity, embryotoxicity and teratogenicity in nonclinical studies at high doses, and therefore itraconazole must not be used during pregnancy. Women of childbearing potential have to use a highly effective method of contraception until the menstrual period after the last itraconazole dose ([R18-2644](#), [R18-2643](#)). For risk mitigation, only male subjects will be included into this clinical trial.

Considering these safety measures and taking into account the reported acceptable tolerability of itraconazole, the planned administration of itraconazole does not represent an undue risk to healthy male volunteers.

Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies

#### 1.4.2.4 Potential interaction between itraconazole and BI 1323495

It is likely that concomitant administration of BI 1323495 with itraconazole may cause an increase of plasma concentrations and  $t_{1/2}$  of BI 1323495. The effect of itraconazole in increasing  $C_{max}$  and AUC of other drugs can be as high as 3.4-fold and 11-fold, respectively, as seen with oral midazolam, a sensitive CYP3A4 substrate, when co-administered with oral itraconazole 200 mg/d ([R01-0516](#), [R18-2644](#)). Inhibition of P-gp may increase exposure of sensitive P-gp substrates like fexofenadine by factor 3-4 ([R08-1652](#), [P07-13746](#)) and increase digoxin exposure by ~1.7-fold ([R15-3252](#)). Therefore, a low dose of BI 1323495 has been selected for this trial (see Section [4.1.2](#)).

#### 1.4.2.5 Safety Measures

- Careful selection of trial population with compound-specific exclusion criteria (see Section [3.3.3](#))
- In-house confinement up to at least 24 hours in period 1 and up to at least 34 hours in period 2, respectively, to cover the period of high plasma exposures
- Safety surveillance with close monitoring for possible changes in safety lab

#### 1.4.2.6 Benefit –Risk Assessment Summary

In summary, BI 1323495 has the potential to become an oral treatment for patients with COPD. Based upon preclinical and clinical data with BI 1323495 and clinical information from competitor compounds as well as the implemented safety measures described above, healthy subjects will not be exposed to undue risks in relation to the important information expected from this trial as a basis for further clinical development of this compound.

Healthy volunteers are not expected to have any direct benefit from participation in this drug-drug-interaction (DDI) trial with BI 1323495 and itraconazole.

Considering the medical need of the development of an effective treatment to slow the progression of COPD for patients with this disease, the Sponsor considers that the benefit outweighs the potential risks and justifies exposure of healthy male volunteers.

## **2. TRIAL OBJECTIVES AND ENDPOINTS**

### **2.1 MAIN OBJECTIVES, PRIMARY AND SECONDARY ENDPOINTS**

#### **2.1.1 Main objectives**

The main objective of this trial is to investigate the relative bioavailability of BI 1323495 in plasma when given as oral single dose together with multiple oral doses of itraconazole (Test, T) as compared to when given alone as oral single dose (Reference, R).

#### **2.1.2 Primary endpoints**

The following pharmacokinetic parameters will be determined for BI 1323495:

- $AUC_{0-tz}$  (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point)
- $C_{max}$  (maximum measured concentration of the analyte in plasma)

#### **2.1.3 Secondary endpoint**

The following pharmacokinetic parameter will be determined for BI 1323495:

- $AUC_{0-\infty}$  (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)

### 2.2.2.2 Safety and tolerability

Safety and tolerability of the trial treatments will be assessed based on:

- Adverse events (including clinically relevant findings from the physical examination)
- Safety laboratory tests
- 12-lead ECG
- Vital signs (blood pressure, pulse rate)

### 3. DESCRIPTION OF DESIGN AND TRIAL POPULATION

#### 3.1 OVERALL TRIAL DESIGN AND PLAN

The study will be performed as an open-label, two-treatment, two-period, one-way crossover trial in healthy male subjects in order to compare the test treatment (T) to the reference treatment (R). The treatments will be one oral single dose of BI 1323495 administered as tablet formulation together with multiple oral doses of 200 mg itraconazole as oral solution formulation (concentration: 10 mg/mL) (T) and one single dose of BI 1323495 as tablet formulation given alone (R).

In both treatments, BI 1323495 is administered to subjects in the fasting state. In the first treatment period (Period 1, Visit 2), all subjects are planned to undergo treatment R, and in the second treatment period (Period 2, Visit 3), all subjects are planned to undergo treatment T. For details, refer to Section [4.1](#).

There will be a washout period of at least 7 days between the administrations of BI 1323495.




Figure 3.1: 1 Trial design

An overview of all relevant trial activities is provided in the [Flow Chart](#). For visit schedule and details of trial procedures at selected visits, refer to Sections [6.1](#) and [6.2](#), respectively.

#### 3.2 DISCUSSION OF TRIAL DESIGN, INCLUDING THE CHOICE OF CONTROL GROUPS

For relative bioavailability trials, the crossover design is preferred because of its efficiency: since each subject serves as his/her own control, the comparison between treatments is based on an intra-subject comparison, thus removing inter-subject variability from the comparison between treatments ([R94-1529](#)). Because of the long half-life (about 40 h) of itraconazole and its metabolites, a fixed sequence design was selected, with administration of itraconazole in the second study period only. This design is not expected to lead to systematic errors in the estimation of the treatment effects since nonspecific time-effects are unlikely due to the short trial duration. For itraconazole studies, this design is recommended by the Innovation and

Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies

Quality in Pharmaceutical Development's Clinical Pharmacology Leadership Group (CPLG) ([R17-3744](#)).

For this PK drug-drug interaction trial, open-label treatment is acceptable, because the primary and secondary endpoints of this trial are PK endpoints derived from measurement of plasma concentrations of BI 1323495. These endpoints are not expected to be affected by knowledge of treatment.

### **3.3 SELECTION OF TRIAL POPULATION**

It is planned that 14 healthy male subjects will enter the study. They will be recruited from the volunteers' pool of the trial site.

Due to the reproduction toxicity itraconazole has shown in nonclinical studies, only male subjects will be included in this trial.

A log of all subjects enrolled into the trial (i.e. who have signed informed consent) will be maintained in the ISF irrespective of whether they have been treated with investigational drug or not.

#### **3.3.1 Main diagnosis for trial entry**

The study will be performed in healthy subjects.

#### **3.3.2 Inclusion criteria**

Subjects will only be included in the trial if they meet the following criteria:

1. Healthy male subjects according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs (BP, PR), 12-lead ECG, and clinical laboratory tests
2. Age of 18 to 50 years (inclusive)
3. BMI of 18.5 to 29.9 kg/m<sup>2</sup> (inclusive)
4. Signed and dated written informed consent prior to admission to the study, in accordance with GCP and local legislation

#### **3.3.3 Exclusion criteria**

Subjects will not be allowed to participate, if any of the following general criteria apply:

1. Any finding in the medical examination (including BP, PR, or ECG) deviating from normal and assessed as clinically relevant by the investigator
2. Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg, diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 45 to 90 bpm
3. Any laboratory value outside the reference range that the investigator considers to be of clinical relevance

Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies

4. Any evidence of a concomitant disease assessed as clinically relevant by the investigator
5. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological, blood coagulation, or hormonal disorders
6. Cholecystectomy or other surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy or simple hernia repair)
7. Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders
8. History of relevant orthostatic hypotension, fainting spells, or blackouts
9. Chronic or relevant acute infections
10. History of relevant allergy or hypersensitivity (including allergy to the trial medication or its excipients)
11. Use of drugs within 30 days of planned administration of trial medication that might reasonably influence the results of the trial (including drugs that cause QT/QTc interval prolongation)
12. Intake of an investigational drug in another clinical trial within 60 days of planned administration of investigational drug in the current trial, or concurrent participation in another clinical trial in which investigational drug is administered
13. Smoker (more than 10 cigarettes or 3 cigars or 3 pipes per day)
14. Inability to refrain from smoking on specified trial days
15. Alcohol abuse (consumption of more than 24 g per day)
16. Drug abuse or positive drug screening
17. Blood donation of more than 100 mL within 30 days of planned administration of trial medication or intended blood donation during the trial
18. Intention to perform excessive physical activities within one week prior to the administration of trial medication or during the trial
19. Inability to comply with the dietary regimen of the trial site
20. A marked baseline prolongation of QT/QTc interval (such as QTc intervals that are repeatedly greater than 450 ms) or any other relevant ECG finding at screening
21. A history of additional risk factors for *Torsade de Pointes* (such as heart failure, hypokalaemia, or family history of Long QT Syndrome)
22. Subject is assessed as unsuitable for inclusion by the investigator, for instance, because the subject is not considered able to understand and comply with study requirements, or has a condition that would not allow safe participation in the study
23. Current or history of relevant kidney, urinary tract diseases or abnormalities (e.g. nephrolithiasis, hydronephrosis, acute or chronic nephritis, renal injury, renal failure)
24. Estimated glomerular filtration rate according to CKD-EPI formula < 90 mL/min at screening
25. Within 10 days prior to administration of trial medication, use of any drug that could reasonably inhibit platelet aggregation or coagulation (e.g., acetylsalicylic acid)
26. History of drug induced liver injury

Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies

27. Liver enzymes (ALT, AST, GGT) above upper limit of normal at the screening examination
28. History of heart failure, or any evidence of ventricular dysfunction
29. Known sorbitol/polyols intolerance
30. Subjects with female partner of childbearing potential who are unwilling to use male contraception (condom or sexual abstinence) from first administration until 30 days after last administration of trial medication

For study restrictions, refer to Section [4.2.2](#).

### 3.3.4 Withdrawal of subjects from treatment or assessments

Subjects may discontinue trial treatment or withdraw consent to trial participation as a whole ('withdrawal of consent') with very different implications; please see Sections 3.3.4.1 and [3.3.4.2](#) below.

If a subject is removed from or withdraws from the trial prior to the first administration of trial medication, the data of this subject will not be entered in the case report form (CRF) and will not be reported in the clinical trial report (CTR). If a subject is removed from or withdraws from the trial after the first administration of trial medication, this will be documented and the reason for discontinuation must be recorded in the CRF; in addition, the data will be included in the CRF and will be reported in the CTR. At the time of discontinuation, a complete end of trial examination will be performed, if possible, and the information will be recorded in the CRF. If the discontinuation occurs before the end of the REP (see Section [1.2.3](#)), the discontinued subject should, if possible, be questioned for AEs and concomitant therapies at or after the end of the REP in order to ensure collection of AEs and concomitant therapies throughout the REP, if not contrary to any consent withdrawal of the subject.

#### 3.3.4.1 Discontinuation of trial treatment

An individual subject will discontinue trial treatment if:

1. The subject wants to discontinue trial treatment, without the need to justify the decision
2. The subject has repeatedly shown to be non-compliant with important trial procedures and, in the opinion of both, the investigator and sponsor representative, is not willing or able to adhere to the trial requirements in the future.
3. The subject needs to take concomitant medication that interferes with the investigational medicinal product or other trial treatment
4. The subject can no longer receive trial treatment for medical reasons (such as surgery, adverse events [AEs], or diseases)
5. The subject experiences a serious adverse drug reaction or a non-serious adverse drug reaction of severe intensity
6. The subject has an elevation of AST and/or ALT  $\geq 3$ -fold ULN
7. The subject has an elevation of AST and/or ALT  $\geq 3$ -fold ULN and an elevation of total bilirubin  $\geq 2$ -fold ULN (measured in the same blood sample) and/or needs to be followed

Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies

up according to the DILI checklist provided in the ISFIn addition to these criteria, the investigator may discontinue subjects at any time based on his or her clinical judgment. Even if the trial treatment is discontinued, the subject remains in the trial and, given his/her agreement, will undergo the procedures for early treatment discontinuation and follow up as outlined in the [Flow Chart](#) and section [6.2.3](#).

#### **3.3.4.2 Withdrawal of consent to trial participation**

Subjects may withdraw their consent to trial participation at any time without the need to justify the decision. If a subject wants to withdraw consent, the investigator should be involved in the discussion with the subject and explain the difference between trial treatment discontinuation and withdrawal of consent to trial participation, as well as explain the options for continued follow up after trial treatment discontinuation, please see Section [3.3.4.1](#) above

#### **3.3.4.3 Discontinuation of the trial by the sponsor**

Boehringer Ingelheim reserves the right to discontinue the trial at any time for any of the following reasons:

1. Failure to meet expected enrolment goals
2. New toxicological findings, serious adverse events, or any safety information invalidating the earlier positive benefit-risk-assessment. More specifically, the trial will be terminated if more than 50% of the subjects have drug-related and clinically relevant adverse events of moderate or severe intensity, if more than two subjects have drug related non-serious adverse events of severe intensity or if at least 1 drug-related serious adverse event is reported.
3. Violation of GCP or the CTP impairing the appropriate conduct of the trial
4. The sponsor decides to discontinue the further development of the investigational product

#### **3.3.5 Replacement of subjects**

Subjects withdrawn due to drug related adverse events will not be replaced. In case more than 2 subjects do not complete the trial, the Clinical Trial Leader together with the Trial Pharmacokineticist and the Trial Statistician are to decide, if and how many subjects will be replaced. A replacement subject will be assigned a unique trial subject number.

## **4. TREATMENTS**

### **4.1 INVESTIGATIONAL TREATMENTS**

The investigational product BI 1323495 as tablet formulation has been manufactured by BI Pharma GmbH & Co. KG. Itraconazole oral solution will be obtained from a public pharmacy.

#### **4.1.1 Identity of the Investigational Medicinal Products**

The characteristics of the test products are given below:

##### Test product 1

Substance: BI 1323495  
Pharmaceutical formulation: Tablet, film-coated  
Source: BI Pharma GmbH & Co. KG, Germany  
Unit strength:  
Posology: 1-0-0  
Route of administration: Oral  
Duration of use: Single dose in treatments R and T

##### Test product 2

Name: Sempera® Liquid 10 mg/mL  
Substance: Itraconazole  
Pharmaceutical formulation: Oral solution  
Source: Public pharmacy  
Holder of marketing authorisation: Janssen-Cilag GmbH, Neuss, Germany  
Unit strength: 10 mg/mL  
Posology: 20 mL-0-0  
Route of administration: Oral  
Duration of use: 10 days in treatment T

#### **4.1.2 Selection of doses in the trial**

##### **Perpetrator (itraconazole)**

The dose of itraconazole selected for this trial reflects standard clinical doses, is considered sufficient to yield significant CYP3A and P-gp inhibition and has been used successfully and safely in previous drug-drug-interaction trials ([c02336088](#), [c03355329](#), [c08928447](#)).

##### **Victim (BI 1323495)**

For the current trial, a dose of BI 1323495 is selected, in order to ensure that BI 1323495 plasma concentrations, even in case of a substantial increase when given with itraconazole, are within the range of concentrations that were explored in the SRD trial 1405-0001 and that were associated with good safety and tolerability (ref. Section [1.4.2.4](#)).

#### **4.1.3 Method of assigning subjects to treatment groups**

There is only one treatment sequence investigated in this trial, and each subject will be allocated to the same treatment sequence (R-T). The subjects will be allocated to a study subject number by drawing lots prior to first administration of trial medication in the morning of Day 1 of Visit 2. Once a subject number has been assigned, it cannot be reassigned to any other subject.

All subjects may be treated in one cohort, i.e. all subjects may receive treatment on the same calendar day. In case this is not feasible (e.g., due to logistical or recruitment reasons), the

Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies

group may be split into several cohorts as required. Treatment of all subjects on the same calendar day is acceptable (for safety margin to exposure reached in previous SRD trial 1405-0001 refer to Section [1.4.2](#); for discussion of study-associated risks and safety measures see Section [1.4.1](#)).

#### **4.1.4 Drug assignment and administration of doses for each subject**

This trial is a one-way crossover study. All subjects will receive the 2 treatments in fixed order. The treatments to be evaluated are outlined in Table 4.1.4: 1 below.

Table 4.1.4: 1                    Dosage and treatment schedule

Treatment period	Treatment	Substance	Formulation	Unit strength	Dosage	Total dose
1	R (Reference)	BI 1323495	Tablet, film-coated		1 tablet as single dose (Day 1)	
2	T (Test)	BI 1323495	Tablet, film-coated		1 tablet as single dose (Day 1)	
	Itraconazole	Oral solution	10 mg/mL	20 mL (200 mg) qd for 10 days (Days -3 to 7)		2000 mg

Administration of trial medication will be performed after subjects have fasted overnight; fasting is to start no later than 10 h before the scheduled dosing of BI 1323495 or 9 hours before itraconazole administration. The investigator (or authorised designee) will administer the trial medication as an oral dose together with about 240 mL of water to subjects who are in a standing position. For drug administration, the so-called four-eye principle (two-person rule) should be applied. For this, one authorised employee of the trial site should witness the administration of trial medication, and – if applicable – its preparation (e.g. reconstitution), if correct dosage cannot be ensured otherwise.

Subjects will be kept under close medical surveillance until at least 24 hours after administration of BI 1323495 in each period. During the first 4 h after administration of BI 1323495, subjects are not allowed to lie down (i.e. no declination of the upper body of more than 45 degrees from upright posture).

The treatments with BI 1323495 will be separated by a wash-out phase of at least 7 days.

#### **4.1.5 Blinding and procedures for unblinding**

This Phase I trial will be handled in an open fashion throughout (that is, during the conduct, including data cleaning and preparation of the analysis). This is considered acceptable because the potential for bias seems to be low and does not outweigh practical considerations.

Emergency envelopes will not be provided, because the dose of trial medication is known to investigators and subjects.

#### **4.1.6 Packaging, labelling, and re-supply**

##### BI 1323495 tablets

BI 1323495 tablets will be provided by BI. They will be packaged and labelled in accordance with local law and the principles of Good Manufacturing Practice. For details of packing and the description of the label, refer to the ISF.

The telephone number of the sponsor and the name, address and telephone number of the trial site are provided in the subject information form. The EudraCT number is indicated on the title page of this protocol as well as on the subject information and informed consent forms.

No re-supply is planned.

##### Itraconazole oral solution

Itraconazole oral solution will be obtained by the clinical trial site from a public pharmacy. The drug will be dispensed out of the original, unmodified packages.

#### **4.1.7 Storage conditions**

Drug supplies will be kept in their original packaging and in a secure limited access storage area in accordance with the recommended (labelled) storage conditions. If necessary, a temperature log must be maintained to make certain that the drug supplies are stored at the correct temperature. If the storage conditions are found to be outside the specified range, the local clinical monitor (as provided in the list of contacts) is to be contacted immediately.

#### **4.1.8 Drug accountability**

The investigator or designee will receive the investigational drugs delivered from the sponsor following requirements are fulfilled:

- Approval of the clinical trial protocol by the IRB / ethics committee
- Approval/notification of the regulatory authority, e.g. competent authority
- Availability of the *curriculum vitae* of the Principal Investigator
- Availability of a signed and dated clinical trial protocol

Only authorised personnel documented in the form 'Trial Staff List' may dispense medication to trial subjects. The trial medication must be administered in the manner specified in the CTP.

The investigator or designee must maintain records of the product's delivery to the trial site, the inventory at the site, the use by each subject, and the disposal of unused products. These records will include dates, quantities, batch / serial numbers, expiry ('use-by') dates, and the unique code numbers assigned to the investigational medicinal product and trial subjects. The investigator or designee will maintain records that document adequately that the subjects were provided the doses specified by the CTP and reconcile all investigational medicinal products received from the sponsor. At the time of disposal of remaining trial medication, the investigator or designee must verify that no remaining supplies are in the investigator's possession.

Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies

All unused medication will be disposed of locally by the trial site upon written authorisation of the Clinical Trial Leader. Receipt, usage and disposal of trial medication must be documented on the appropriate forms. Account must be given for any discrepancies.

## **4.2 OTHER TREATMENTS, EMERGENCY PROCEDURES, RESTRICTIONS**

### **4.2.1 Other treatments and emergency procedures**

There are no special emergency procedures to be followed. No additional treatment is planned. However, if adverse events require treatment, the investigator can authorise symptomatic therapy. In those cases, subjects will be treated as necessary and, if required, kept under supervision at the trial site or transferred to a hospital until all results of medical evaluations are acceptable.

### **4.2.2 Restrictions**

#### **4.2.2.1 Restrictions regarding concomitant treatment**

In principle, no concomitant therapy is allowed. All concomitant or rescue therapies will be recorded (including time of intake on study days) on the appropriate pages of the CRF.

Known inhibitors/inducers of CYP3A and P-gp activity, drugs with a known hepatotoxicity profile, drugs which are contraindicated to be co-administered with itraconazole (ref. [R18-2644](#)),

should be avoided during the entire study; if necessary, short term use of ibuprofen is acceptable.

#### **4.2.2.2 Restrictions on diet and life style**

Poppy-seeds containing foods should not be consumed starting 3 days before the first drug administration in each treatment period, in order to avoid false-positive results in the drug-screen.

While admitted to the trial site, the subjects will be instructed not to consume any foods or drinks other than those provided by the staff. Standardised meals will be served at the times indicated in the [Flow Chart](#).

No food is allowed within 10 h before and for at least 4 h after intake of BI 1323495. Subjects will be advised to not consume any food within 9 h before and 1 h after itraconazole administrations.

On Day 1, from 1 h before intake of BI 1323495 (Period 1) or itraconazole (Period 2), respectively, fluid intake is restricted to the water administered with the drug, and an additional 240 mL of water at 2 h and 4 h post-dose (mandatory for all subjects). From lunch until 23 h post-dose, total fluid intake is restricted to 3000 mL.

Grapefruits, Seville oranges (sour or bitter oranges) and their juices, and dietary supplements and products containing St. John's wort (*Hypericum perforatum*) are not permitted from 7

Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies

days before the first administration of trial medication in Period 1 until after the last PK sample of Period 2 is collected.

Alcoholic beverages are not permitted from 3 days before the first administration of trial medication in Period 1 until after the last PK sample in Period 2 is collected.

Methylxanthine-containing drinks or foods (such as coffee, tea, cola, energy drinks, or chocolate) are not allowed from 10 h before until 24 h after administration of BI 1323495.

Smoking is not allowed during in-house confinement.

Excessive physical activity (such as competitive sport) should be avoided from 7 days before the first administration of trial medication until the end of trial examination.

Direct exposure to the sun or exposure to solarium radiation should be avoided during the entire study.

#### **4.3 TREATMENT COMPLIANCE**

Compliance will be assured by administration of all trial medication in the study centre under supervision of the investigating physician or a designee. The measured plasma concentrations of trial medication will provide additional confirmation of compliance.

Subjects who are non-compliant (for instance, who do not appear for scheduled visits or violate trial restrictions) may be removed from the trial and the CRF will be completed accordingly (for further procedures, please see Section [3.3.4.1](#)).

## **5. ASSESSMENTS**

### **5.1 ASSESSMENT OF EFFICACY**

Not applicable.

### **5.2 ASSESSMENT OF SAFETY**

#### **5.2.1 Physical examination**

At screening, the medical examination will include demographics, height and body weight, smoking and alcohol history (results of alcohol history not mandatory to be entered into CRF or to be reported), relevant medical history and concomitant therapy, review of inclusion and exclusion criteria, review of vital signs (BP, PR), 12-lead ECG, laboratory tests, and a physical examination. At the end of trial examination, it will include review of vital signs, 12-lead ECG, laboratory tests, and a physical examination.

#### **5.2.2 Vital signs**

Systolic and diastolic blood pressures (BP) as well as pulse rate (PR) or heart rate (heart rate is considered to be equal to pulse rate) will be measured by a blood pressure monitor (Dinamap Pro 100, GE Medical Systems, Freiburg, Germany) at the times indicated in the [Flow Chart](#), after subjects have rested for at least 5 min in a supine position. All recordings should be made using the same type of blood pressure recording instrument on the same arm, if possible.

#### **5.2.3 Safety laboratory parameters**

For the assessment of laboratory parameters, blood and urine samples will be collected by the trial site at the times indicated in the Flow Chart after the subjects have fasted for at least 10 h. For retests, at the discretion of the investigator or designee, and for timepoints with liver function tests only (parameter set C) overnight fasting is not required.

The parameters that will be determined are listed in Tables [5.2.3: 1](#) and [5.2.3: 2](#). Reference ranges will be provided in the ISF, Section 10.

Manual differential white blood cell count or urine sediment examinations will only be performed if there is an abnormality in the automatic blood cell count or in the urinalysis, respectively.

Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies

Table 5.2.3: 1

Routine laboratory tests

Functional lab group	BI test name [comment/abbreviation]	A <sup>1</sup>	B <sup>1</sup>	C <sup>1</sup>	D <sup>1</sup>
Haematology	Haematocrit Haemoglobin Red Blood Cell Count/Erythrocytes White Blood Cells/Leucocytes Platelet Count/Thrombocytes (quant)	X X X X X	X X X X X	-- -- -- -- --	X X X X X
Automatic WBC differential, relative	Neutrophils/Leukocytes; Eosinophils/Leukocytes; Basophils/Leukocytes; Monocytes/Leukocytes; Lymphocytes/Leukocytes	X	X	--	X
Automatic WBC differential, absolute	Neutrophil, absol.; Eosinophils, absol.; Basophils, absol.; Monocytes, absol.; Lymphocytes, absol.	X	X	--	X
Manual differential WBC <sup>2</sup> (if automatic differential WBC is abnormal)	Neut. Poly (segs); Neut. Poly (segs), absol.; Neutrophils Bands; Neutrophils Bands, absol.; Eosinophils/Leukocytes; Eosinophils, absol.; Basophils/ Leukocytes; Basophils, absol.; Monocytes/ Leukocytes; Monocytes, absol.; Lymphocytes/Leukocytes; Lymphocytes, absol.				
Coagulation	Activated Partial Thromboplastin Time Prothrombin time INR (International Normalization Ratio) Fibrinogen	X X X X	-- -- -- X	-- -- -- --	X X X X
Enzymes	AST [Aspartate transaminase] /GOT, SGOT ALT [Alanine transaminase] /GPT, SGPT Alkaline Phosphatase Gamma-Glutamyl Transferase) Glutamate Dehydrogenase (GLDH) Creatine Kinase [CK] Creatine Kinase Isoenzyme MB [only if CK is elevated]	X X X X X X	X X X X X X	X X X X -- --	X X X X X X
Hormones	Thyroid Stimulating Hormone	X	--	--	--
Substrates	Glucose (Plasma) Creatinine GFR/ CKD-EPI <sup>3</sup> Bilirubin, Total Bilirubin, Direct Protein, Total C-Reactive Protein (Quant) Cholesterol, total Triglyceride	X X X X X X X X	X X X X X X -- --	-- -- -- -- -- -- -- --	X X X X X X X X
Electrolytes	Sodium Potassium	X X	X X	-- --	X X

<sup>1</sup> A: parameters to be determined at Visit 1 (screening examination)

B: parameters to be determined at Visit 2 and 3 (for study days and time points refer to [Flow Chart](#))

C: parameters to be determined at Visit 3 (for study days and time points refer to Flow Chart)

D: parameters to be determined at Visit 4 (end of trial examination)

<sup>2</sup> Manual differential WBC if automatic differential WBC is abnormal

<sup>3</sup> Estimated glomerular filtration rate according to CKD-EPI formula ([R12-1392](#))

Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies

**Table 5.2.3: 1** Routine laboratory tests (cont.)

Functional lab group	BI test name [comment/abbreviation]	A <sup>1</sup>	B <sup>1</sup>	C <sup>1</sup>	D <sup>1</sup>
Urinalysis (Stix)	Urine Nitrite (qual)	X	X	--	X
	Urine Protein (qual)	X	X	--	X
	Urine Glucose (qual)	X	X	--	X
	Urine Ketone (qual)	X	X	--	X
	Urobilinogen (qual)	X	X	--	X
	Urine Bilirubin (qual)	X	X	--	X
	Urine RBC/Erythrocytes (qual)	X	X	--	X
	Urine WBC/Leucocytes (qual)	X	X	--	X
	Urine pH	X	X	--	X
Urine sediment <sup>2</sup>	Only positive findings will be reported (for instance, the presence of sediment bacteria, casts in sediment, squamous epithelial cells, erythrocytes, leukocytes)				

<sup>1</sup> A: parameters to be determined at Visit 1 (screening examination)

B: parameters to be determined at Visit 2 and 3 (for study days and time points refer to [Flow Chart](#))

C: parameters to be determined at Visit 3 (for study days and time points refer to Flow Chart)

D: parameters to be determined at Visit 4 (end of trial examination)

<sup>2</sup> Microscopic examination if erythrocytes, leukocytes, nitrite or protein in urinalysis are abnormal in urine

The tests listed in Table 5.2.3: 2 are exclusionary laboratory tests that may be repeated as required. The results will not be entered in the CRF/database and will not be reported in the CTR. Infectious serology is planned to perform these tests during screening only. Drug screening will be performed at screening and prior to first dose in each treatment period.

**Table 5.2.3: 2** Exclusionary laboratory tests

Functional lab group	Test name
Drug screening (urine)	Amphetamine/MDA
	Barbiturates
	Benzodiazepine
	Cannabis
	Cocaine
	Methadone
	Methamphetamines/MDMA/XTC
	Opiates
	Phencyclidine
	Tricyclic antidepressants
Infectious serology (blood)	Hepatitis B surface antigen (qualitative)
	Hepatitis B core antibody (qualitative)
	Hepatitis C antibodies (qualitative)
	HIV-1 and HIV-2 antibody (qualitative)

To encourage compliance with alcoholic restrictions, a breath alcohol test (e.g. Alcotest® 7410, Dräger AG, Lübeck, Germany) will be performed prior to first dose in each treatment period, and may be repeated at any time during the study at the discretion of an investigator or designee. The results will not be included in the CTR.

The laboratory tests listed in Tables [5.2.3: 1](#) and [5.2.3: 2](#) will be performed at  
with the exception of

Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies

drug screening. This test will be performed at the trial site using M-10/14-PDT test or a comparable test system.

Laboratory data will be transmitted electronically from the laboratory to the trial site.

#### **5.2.4      Electrocardiogram**

Twelve-lead ECGs (I, II, III, aVR, aVL, aVF, V1 - V6) will be recorded using a computerised electrocardiograph (CardioSoft EKG System, GE Medical Systems, Freiburg, Germany) at the times provided in the [Flow Chart](#).

To achieve a stable heart rate at rest and to assure high quality recordings, the site personnel will be instructed to assure a relaxed and quiet environment, so that all subjects are at complete rest.

All ECGs will be recorded for 10 sec duration after subjects have rested for at least 5 min in a supine position. ECG assessment will always precede all other study procedures scheduled for the same time to avoid compromising ECG quality.

All ECGs will be stored electronically on the Muse CV Cardiology System (GE Medical Systems, Freiburg, Germany). Electrode placement will be performed according to the method of Wilson, Goldberger and Einthoven modified by Mason and Likar (hips and shoulders instead of ankles and wrists).

All locally printed ECGs will be evaluated by the investigator or a designee. Abnormal findings will be reported as AEs (during the trial) or baseline conditions (at screening) if assessed to be clinically relevant by the investigator. Any ECG abnormalities will be carefully monitored and, if necessary, the subject will be removed from the trial and will receive the appropriate medical treatment.

ECGs may be repeated for quality reasons (for instance, due to alternating current artefacts, muscle movements, or electrode dislocation) and the repeated ECG will be used for analysis. Additional (unscheduled) ECGs may be collected by the investigator for safety reasons.

#### **5.2.5      Other safety parameters**

Not applicable.

#### **5.2.6      Assessment of adverse events**

##### **5.2.6.1      Definitions of adverse events**

###### **5.2.6.1.1      Adverse event**

An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a medicinal product and which does not necessarily have to have a causal relationship with this treatment.

An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies

The following should also be recorded as an AE in the CRF and BI SAE form (if applicable):

- Worsening of the underlying disease or of other pre-existing conditions
- Changes in vital signs, ECG, physical examination, and laboratory test results, if they are judged clinically relevant by the investigator

If such abnormalities already pre-exist prior to trial inclusion, they will be considered as baseline conditions and should be collected in the eCRF only.

#### 5.2.6.1.2 Serious adverse event

A serious adverse event (SAE) is defined as any AE which fulfils at least one of the following criteria:

- Results in death
- Is life-threatening, which refers to an event in which the patient was at risk of death at the time of the event; it does not refer to an event that hypothetically might have caused death if more severe
- Requires inpatient hospitalisation
- Requires prolongation of existing hospitalisation
- Results in persistent or significant disability or incapacity
- Is a congenital anomaly/birth defect
- Is deemed serious for any other reason if it is an important medical event when based upon appropriate medical judgment which may jeopardise the patient and may require medical or surgical intervention to prevent one of the other outcomes listed in the above definitions. Examples of such events are intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospitalisation or development of dependency or abuse

#### 5.2.6.1.3 AEs considered ‘Always Serious’

Cancers of new histology and exacerbations of existing cancer must be classified as a serious event regardless of the time since discontinuation of the trial medication and must be reported as described in [5.2.6.2](#), subsections ‘AE Collection’ and ‘**AE reporting to sponsor and timelines**’.

In accordance with the European Medicines Agency initiative on Important Medical Events, Boehringer Ingelheim has set up a list of further AEs, which, by their nature, can always be considered to be ‘serious’ even though they may not have met the criteria of an SAE as defined above.

The latest list of ‘Always Serious AEs’ can be found in the eDC system, an electronic data capture system which allows the entry of trial data at the trial site. These events should always be reported as SAEs as described above.

Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies

#### 5.2.6.1.4 Adverse events of special interest

The term adverse events of special interest (AESI) relates to any specific AE that has been identified at the project level as being of particular concern for prospective safety monitoring and safety assessment within this trial, e.g. the potential for AEs based on knowledge from other compounds in the same class. AESIs need to be reported to the sponsor's Pharmacovigilance Department within the same timeframe that applies to SAEs, please see section [5.2.6.2.2](#).

The following are considered as AESIs:

- Hepatic injury  
A hepatic injury is defined by the following alterations of hepatic laboratory parameters:
  - o An elevation of AST (aspartate transaminase) and/or ALT (alanine transaminase)  $\geq 3$ -fold ULN combined with an elevation of total bilirubin  $\geq 2$ -fold ULN measured in the same blood sample, or
  - o Aminotransferase (ALT, and/or AST) elevations  $\geq 10$  fold ULN

These lab findings constitute a hepatic injury alert and the subjects showing these lab abnormalities need to be followed up according to the 'DILI checklist' provided in the ISF. In case of clinical symptoms of hepatic injury (icterus, unexplained encephalopathy, unexplained coagulopathy, right upper quadrant abdominal pain, etc.) without lab results (ALT, AST, total bilirubin) available, the Investigator should make sure that these parameters are analysed, if necessary in an unscheduled blood test. Should the results meet the criteria of hepatic injury alert, the procedures described in the DILI checklist should be followed.

#### 5.2.6.1.5 Intensity (severity) of AEs

The intensity (severity) of the AE should be judged based on the following:

Mild: Awareness of sign(s) or symptom(s) that is/are easily tolerated  
Moderate: Sufficient discomfort to cause interference with usual activity  
Severe: Incapacitating or causing inability to work or to perform usual activities

#### 5.2.6.1.6 Causal relationship of AEs

Medical judgment should be used to determine the relationship, considering all relevant factors, including pattern of reaction, temporal relationship, de-challenge or re-challenge, confounding factors such as concomitant medication, concomitant diseases and relevant history.

Arguments that may suggest that there is a reasonable possibility of a causal relationship could be:

- The event is consistent with the known pharmacology of the drug
- The event is known to be caused by or attributed to the drug class
- A plausible time to onset of the event relative to the time of drug exposure

Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies

- Evidence that the event is reproducible when the drug is re-introduced
- No medically sound alternative aetiologies that could explain the event (e.g. pre-existing or concomitant diseases, or co-medications)
- The event is typically drug-related and infrequent in the general population not exposed to drugs (e.g. Stevens-Johnson syndrome)
- An indication of dose-response (i.e. greater effect size if the dose is increased, smaller effect size if dose is reduced)

Arguments that may suggest that there is no reasonable possibility of a causal relationship could be:

- No plausible time to onset of the event relative to the time of drug exposure is evident (e.g. pre-treatment cases, diagnosis of cancer or chronic disease within days / weeks of drug administration; an allergic reaction weeks after discontinuation of the drug concerned)
- Continuation of the event despite the withdrawal of the medication, taking into account the pharmacological properties of the compound (e.g. after 5 half-lives). Of note, this criterion may not be applicable to events whose time course is prolonged despite removing the original trigger
- Additional arguments amongst those stated before, like alternative explanation (e.g. situations where other drugs or underlying diseases appear to provide a more likely explanation for the observed event than the drug concerned)
- Disappearance of the event even though the trial drug treatment continues or remains unchanged

### 5.2.6.2 Adverse event collection and reporting

#### 5.2.6.2.1 AE collection

Upon enrolment into a trial, the subject's baseline condition is assessed (for instance, by documentation of medical history/concomitant diagnoses), and relevant changes from baseline are noted subsequently.

Subjects will be required to report spontaneously any AEs as well as the time of onset, end time, and intensity of these events. In addition, each subject will be regularly assessed by the medical staff throughout the clinical trial and whenever the investigator deems necessary. As a minimum, subjects will be questioned for AEs (and concomitant therapies) at the time points indicated in the [Flow Chart](#). Assessment will be made using non-specific questions such as 'How do you feel?'. Specific questions will be asked wherever necessary in order to more precisely describe an AE.

A carefully written record of all AEs shall be kept by the investigator in charge of the trial. Records of AEs shall include data on the time of onset, end time, intensity of the event, and any treatment or action required for the event and its outcome.

The following must be collected and documented on the appropriate CRF(s) by the investigator:

- From signing the informed consent onwards until an individual subject's end of trial:

Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies

- All AEs (serious and non-serious) and all AESIs
- The only exception to this rule are AEs (serious and non-serious) and AESIs in Phase I trials in healthy volunteers, when subjects discontinue from the trial due to screening failures prior to administration of any trial medication. In these cases, the subjects' data must be collected at trial site but will not be entered in the CRF or trial database and will not be reported in the CTR.
- After the individual subject's end of trial:
  - The investigator does not need to actively monitor the subject for AEs but should only report any occurrence of cancer and related SAEs and related AESIs of which the investigator may become aware of by any means of communication, e.g. phone call. Those AEs should, however, not be reported in the CRF.

#### **5.2.6.2.2 AE reporting to the sponsor and timelines**

The Investigator must report SAEs, AESIs, and non-serious AEs which are relevant for the reported SAE or AESI, on the BI SAE form via fax immediately (within 24 hours) to the sponsor's unique entry point (country specific contact details will be provided in the ISF). The same timeline applies if follow-up information becomes available. In specific occasions, the Investigator could inform the sponsor upfront via telephone. This does not replace the requirement to complete and fax the BI SAE form.

With receipt of any further information to these events, a follow-up SAE form has to be provided. For follow-up information, the same rules and timeline apply as for initial information.

#### **5.2.6.2.3 Information required**

All (S)AEs, including those persisting after the individual subject's end of trial, must be followed up until they have resolved, have been sufficiently assessed as 'chronic' or 'stable', or no further information can be obtained.

#### **5.2.6.2.4 Pregnancy**

Once the male subject has been enrolled in the clinical trial and has taken trial medication, and if a partner of the male trial participant becomes pregnant, the investigator must report any drug exposure during pregnancy in a partner of the male trial participant immediately (within 24 hours) by means of Part A of the Pregnancy Monitoring Form to the sponsor's unique entry point, after a written consent of the pregnant partner.

The outcome of the pregnancy associated with the drug exposure during pregnancy must be followed up and reported to the sponsor's unique entry point on the Pregnancy Monitoring Form for Clinical Trials (Part B).

The ISF will contain the Pregnancy Monitoring Form for Clinical Trials (Part A and Part B) as well as non-trial specific information and consent for the pregnant partner.

As pregnancy itself is not to be reported as an AE, in the absence of an accompanying SAE and/or AESI, only the Pregnancy Monitoring Form for Clinical Trials and not the SAE form

Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies

is to be completed. If there is an SAE and/or AESI associated with the pregnancy, an SAE form must be completed in addition.

## **5.3 DRUG CONCENTRATION MEASUREMENTS AND PHARMACOKINETICS**

### **5.3.1 Assessment of pharmacokinetics**

For the assessment of pharmacokinetics, blood samples will be collected at the time points indicated in the [Flow Chart](#). The actual sampling times will be recorded and used for determination of pharmacokinetic parameters.

### **5.3.2 Methods of sample collection**

#### **5.3.2.1 Blood sampling for pharmacokinetic analysis of BI 1323495**

For quantification of BI 1323495 concentrations in plasma, 2.7 mL of blood will be drawn from an antecubital or forearm vein into a K<sub>2</sub>-EDTA (dipotassium ethylenediaminetetraacetic acid)-anticoagulant blood drawing tube at the times indicated in the Flow Chart. Blood will be withdrawn by means of either an indwelling venous catheter or by venepuncture with a metal needle.

At a minimum, the sample tube labels should list BI trial number, subject number, visit, planned sampling time, and the analyte (BI 1323495).

#### **5.3.2.2 Blood sampling for pharmacokinetic analysis of itraconazole**

For quantification of itraconazole concentrations in plasma, 2.7 mL of blood will be drawn from an antecubital or forearm vein into a K<sub>2</sub>-EDTA anticoagulant blood drawing tube at the times indicated in the Flow Chart. Blood will be withdrawn by means of either an indwelling venous catheter or by venepuncture with a metal needle.

At a minimum, the sample tube labels should list BI trial number, subject number, visit, planned sampling time, and the analyte 'Itra'.

### **5.3.3 Analytical determinations**

#### **5.3.3.1 Analytical determination of analyte plasma concentration**

BI 1323495 as well as itraconazole concentrations in plasma will be determined by validated LC-MS/MS (liquid chromatography tandem mass spectrometry) assays. All details of the analytical method will be available prior to the start of sample analysis.

#### **5.3.3.2 Further use of plasma samples**

After completion of the quantification of BI 1323495 and itraconazole in plasma, the left-over and/or back-up aliquots may be used for further methodological investigations, e.g. for stability testing or assessments of metabolites (including, if applicable, re-analysis of parent compound). However, only data related to the analyte and/or its metabolite(s) including anti-drug antibodies (if applicable) will be generated by these additional investigations. The study samples will be discarded after completion of the additional investigations but not later than 5 years after the CTR is archived.

The results of any further investigations are not planned to be part of the CTR but can be included into the CTR if necessary.

## **5.4 BIOBANKING**

Not applicable.

## **5.5 OTHER ASSESSMENTS**

## **5.6 APPROPRIATENESS OF MEASUREMENTS**

All measurements performed during this trial are standard measurements and will be performed in order to monitor subjects' safety and to determine pharmacokinetic parameters in an appropriate way. The scheduled measurements will allow monitoring of changes in vital signs, standard laboratory values, and ECG parameters that might occur as a result of administration of trial medication. The safety assessments are standard, are accepted for evaluation of safety and tolerability of an orally administered drug, and are widely used in clinical trials. The pharmacokinetic parameters and measurements outlined in Section [5.4](#) are generally used assessments of drug exposure.

## **6. INVESTIGATIONAL PLAN**

### **6.1 VISIT SCHEDULE**

Exact times of measurements outside the permitted time windows will be documented. The acceptable time windows for screening, the end of trial examination, and measurements and assessments scheduled to occur 'before' trial medication administrations are provided in the [Flow Chart](#).

If not stated otherwise in the Flow Chart, the acceptable deviation from the scheduled time for the assessment of safety (e.g. vital signs, ECG, laboratory tests) will be  $\pm 30$  min.

If scheduled in the Flow Chart at the same time as a meal, blood sampling, vital signs, and 12-lead ECG recordings have to be done first. Furthermore, if several measurements including venepuncture are scheduled for the same time, venepuncture should be the last of the measurements due to its inconvenience to the subject and possible influence on physiological parameters.

For planned blood sampling times, refer to the Flow Chart. While these nominal times should be adhered to as closely as possible, the actual sampling times will be recorded and used for the determination of pharmacokinetic parameters.

If a subject misses an appointment, it will be rescheduled if possible. The relevance of measurements outside the permitted time windows will be assessed no later than at the Report Planning Meeting.

### **6.2 DETAILS OF TRIAL PROCEDURES AT SELECTED VISITS**

#### **6.2.1 Screening period**

After having been informed about the trial, all subjects will provide written informed consent in accordance with GCP and local legislation prior to enrolment in the study.

For information regarding laboratory tests (including drug and virus screening), ECG, vital signs, and physical examination, refer to Sections [5.2.3](#) to [5.2.5](#).

#### **6.2.2 Treatment periods**

Each subject is expected to participate in 2 treatment periods (Days -3 to -1, 1, 2, 3, 4, and 5 in Period 1 and Days -3, -2, -1, 1, 2, 3, 4, 5, 6, 7, and 8 in Period 2). At least 7 days will separate BI 1323495 drug administrations in the first and second treatment period.

On Day 1 of each treatment period, study participants will be admitted to the trial site. They will be kept under close medical surveillance for at least 24 h (period 1) and 34 h (period 2) following administration of BI 1323495, respectively. The subjects will then be allowed to leave the trial site after formal assessment and confirmation of their fitness. On all other study days, subjects will be treated in an ambulatory fashion.

Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies

For details on time points and procedures for collection of plasma samples for PK analysis, refer to [Flow Chart](#) and Section [5.3.2](#).

The safety measurements performed during the treatment period are specified in Section [5.3](#) of this protocol and in the Flow Chart. For details on times of all other trial procedures, refer to the Flow Chart. AEs and concomitant therapy will be assessed continuously from screening until the end of trial examination.

### **6.2.3 Follow-up period and trial completion**

For AE assessment, laboratory tests, recording of ECG and vital signs, and physical examination during the follow-up period, see Sections [5.2.2](#) to [5.2.6](#).

Subjects who discontinue treatment before the end of the planned treatment period should undergo the EoTrial Visit.

All abnormal values (including laboratory parameters) that are assessed as clinically relevant by the investigator will be monitored using the appropriate tests until a return to a medically acceptable level is achieved. (S)AEs persisting after a subject's EoTrial Visit must be followed until they have resolved, have been sufficiently characterised, or no further information can be obtained.

## 7. STATISTICAL METHODS AND DETERMINATION OF SAMPLE SIZE

### 7.1 STATISTICAL DESIGN – MODEL

The main objective of this trial is to investigate the relative bioavailability of BI 1323495 in plasma when given as oral single dose together with multiple doses of itraconazole (Test, T) as compared to when given alone as oral single dose (Reference, R) on the basis of the primary and secondary pharmacokinetic endpoints, as listed in Sections [2.1.2](#) and [2.1.3](#). The trial will be conducted as a two-treatment, two-period, fixed-sequence design, which allows intra-subject comparisons. It will be evaluated statistically by use of a linear model for logarithmically transformed PK endpoints.

The assessment of safety and tolerability is a further objective of this trial, and will be evaluated by descriptive statistics for the parameters specified in Section [2.2.2.2](#).

### 7.2 NULL AND ALTERNATIVE HYPOTHESES

The relative bioavailability of BI 1323495 in plasma when given with multiple oral doses of itraconazole (T) versus single oral dose of BI 1323495 alone (R) will be estimated by the ratios of the geometric means (T/R), and their corresponding 2-sided 90% confidence intervals (CIs) will be provided. This method corresponds to the two one-sided t-test procedure, each at the 5% significance level. Since the main focus is on estimation and not testing, a formal hypothesis test and associated acceptance range is not specified.

### 7.3 PLANNED ANALYSES

#### Analysis sets

Statistical analyses will be based on the following analysis sets:

- Treated set (TS): The treated set includes all subjects who were entered and treated with at least one dose of study drugs. The treated set will be used for safety analyses.
- Pharmacokinetic analysis set (PKS): This set includes all subjects in the treated set (TS) who provide at least one PK endpoint that was defined as primary or secondary and was not excluded due to a protocol deviation relevant to the evaluation of PK or due to PK non-evaluability (as specified in the following subsection ‘Pharmacokinetics’). Thus, a subject will be included in the PKS, even if he contributes only one PK parameter value for one period to the statistical assessment. Descriptive and model based analyses of PK parameters will be based on the PKS.

Adherence to the protocol will be assessed by the trial team. Important protocol deviation (IPD) categories will be suggested in the IQRM plan, IPDs will be identified no later than in the Report Planning Meeting, and the IPD categories will be updated as needed.

## Pharmacokinetics

The pharmacokinetic parameters listed in Sections [2.1](#) and [2.2](#) for BI 1323495 will be calculated according to the relevant SOP of the Sponsor ([001-MCS-36-472](#)).

Plasma concentration data and parameters of a subject will be included in the statistical pharmacokinetic (PK) analyses if they are not flagged for exclusion due to a protocol deviation relevant to the evaluation of PK (to be decided no later than in the Report Planning Meeting) or due to PK non-evaluability (as revealed during data analysis, based on the criteria specified below). Exclusion of a subject's data will be documented in the CTR.

Relevant protocol deviations may be

- Incorrect trial medication taken, i.e. the subject received at least one dose of trial medication the subject was not assigned to
- Incorrect dose of trial medication taken
- Use of restricted medications

Plasma concentrations and/or parameters of a subject will be considered as non-evaluable, if for example

- The subject experienced emesis that occurred at or before two times median  $t_{max}$  of the respective treatment (Median  $t_{max}$  is to be determined excluding the subjects experiencing emesis)
- A predose concentration of BI 1323495 is  $>5\%$   $C_{max}$  value of that subject in the respective treatment period
- Missing samples/concentration data at important phases of PK disposition curve

Plasma concentration data and parameters of a subject which is flagged for exclusion will be reported with its individual values but will not be included in the statistical analyses.

Descriptive and inferential statistics of PK parameters will be based on the PKS.

Only concentration values within the validated concentration range and actual sampling times will be used for the calculation of pharmacokinetic parameters. Concentrations used in the pharmacokinetic calculations will be in the same format provided in the bioanalytical report, (that is, to the same number of decimal places provided in the bioanalytical report).

### 7.3.1 Primary endpoint analyses

#### Primary analyses

The statistical model used for the analysis of the primary endpoints will be an analysis of variance (ANOVA) model on the logarithmic scale. That is, the PK endpoints will be log-transformed (natural logarithm) prior to fitting the ANOVA model. This model will include effects accounting for the following sources of variation: subject and treatment. The effect 'subject' will be considered as random, whereas the effect 'treatment' will be considered as fixed. The model is described by the following equation:

$y_{km} = \mu + s_m + \tau_k + e_{km}$ , where

$y_{km}$  = logarithm of response measured on subject m receiving treatment k,

$\mu$  = the overall mean,

$s_m$  = the effect associated with the m<sup>th</sup> subject, m = 1, 2, ..., n,

$\tau_k$  = the k<sup>th</sup> treatment effect, k = 1, 2,

$e_{km}$  = the random error associated with the m<sup>th</sup> subject who received treatment k.

where  $s_m \sim N(0, \sigma_B^2)$  i.i.d.,  $e_{km} \sim N(0, \sigma_W^2)$  i.i.d. and  $s_m, e_{km}$  are independent random variables. The indices 'B' and 'W' correspond to 'between' and 'within' variability, respectively.

Point estimates for the ratios of the geometric means (test/reference) for the primary endpoints (see Section [2.1](#)) and their two-sided 90% confidence intervals (CIs) will be provided.

For each endpoint, the difference between the expected means for log(T)-log(R) will be estimated by the difference in the corresponding adjusted means (Least Squares Means). Additionally their two-sided 90% confidence intervals will be calculated based on the residual error from the ANOVA and quantiles from the t-distribution. These quantities will then be back-transformed to the original scale to provide the point estimate and 90% CIs for each endpoint.

### **7.3.2 Secondary endpoint analyses**

The secondary endpoints (refer to Section [2.1.3](#)) will be calculated according to the BI SOP 'Standards and processes for analyses performed within Clinical Pharmacokinetics/ Pharmacodynamics' ([001-MCS-36-472](#)) and will be assessed statistically using the same methods as described for the primary endpoints.

### **7.3.4 Safety analyses**

Safety will be analysed based on the assessments described in Section [2.2.2.2](#). All treated subjects (TS, refer to Section [7.2](#)) will be included in the safety analysis. Safety analyses will be descriptive in nature and based on BI standards. No hypothesis testing is planned.

For all analyses, the treatment actually administered (= treatment at onset) to the subject will be used (any deviations will be discussed in the Report Planning Meeting).

Treatments will be compared in a descriptive way. Tabulations of frequencies/proportions will be used to evaluate categorical (qualitative) data, and tabulations of descriptive statistics will be used to analyse continuous (quantitative) data.

Measurements (such as ECG, vital signs, or laboratory parameters) or AEs will be assigned to treatments (see Section [4.1](#)) based on the actual treatment at the planned time of the measurement or on the recorded time of AE onset (concept of treatment emergent AEs).

Therefore, measurements planned or AEs recorded prior to first intake of trial medication will be assigned to the screening period, those between first trial medication intake and end of REP (see Section [1.2.3](#)) will be assigned to the treatment period. Events occurring after the REP but prior to next intake or end of trial termination date will be assigned to 'follow-up'. In case of two or more treatments, the follow-up will be summarized according to the previous treatment. These assignments including the corresponding time intervals will be defined in detail in the TSAP. Note that AEs occurring after the last per protocol contact but entered before final database lock will be reported to Pharmacovigilance only and will not be captured in the trial database.

Additionally, further treatment intervals (analysing treatments) may be defined in the TSAP in order to provide summary statistics for time intervals, such as combined treatments, on-treatment totals, or periods without treatment effects (such as screening and follow-up intervals).

Adverse events will be coded using the Medical Dictionary for Regulatory Activities (MedDRA). Frequency, severity, and causal relationship of AEs will be tabulated by treatment, system organ class, and preferred term. SAEs, AESIs (see Section [5.2.6.1](#)), and other significant AEs (according to ICH E3) will be listed separately.

Previous and concomitant therapies will be presented per treatment group without consideration of time intervals and treatment periods.

Laboratory data will be compared to their reference ranges. Values outside the reference range as well as values defined as possibly clinically significant will be highlighted in the listings. Additionally, differences from baseline will be evaluated.

Vital signs or other safety-relevant data will be assessed with regard to possible on-treatment changes from baseline.

Relevant ECG findings will be reported as AEs.

## **7.4 INTERIM ANALYSES**

No interim analysis is planned.

## **7.5 HANDLING OF MISSING DATA**

### **7.5.1 Safety**

It is not planned to impute missing values for safety parameters.

### **7.5.2 Pharmacokinetics**

Handling of missing PK data will be performed according to the relevant Corporate Procedure ([001-MCS-36-472](#)).

PK parameters that cannot be reasonably calculated based on the available drug concentration-time data will not be imputed.

## **7.6 RANDOMISATION**

Randomisation is not applicable in this open-label, single arm study. All subjects will receive the same treatments in the same order

## **7.7 DETERMINATION OF SAMPLE SIZE**

It is planned to enter a total of 14 subjects in the trial, accounting for up to 2 dropouts or non PK evaluable subjects. The planned sample size is not based on a power calculation but is considered sufficient to achieve the aims of this exploratory trial.

With this sample size, the following precision in estimating the ratio of geometric means (T/R) can be expected with 95% tolerance probability. Precision is defined as the ratio of upper CI limit to the relative BA estimate. Note that the precision is independent of the actual ratio of geometric means.

The observed coefficient of variation (gCV%) after a single oral dose of BI 1323495 in trial 1405-0001 was roughly 66.3% for  $C_{max}$  and 104% for AUC. The reported variability originated from a parallel group estimates total variability. However, for this trial as a crossover trial intra-individual gCV is needed. Assuming the correlation between two responses of the same subjects  $\rho=0.5$  for  $C_{max}$  and  $\rho=0.75$  for AUC, we can estimate the intra-individual variability out of the total variability. The calculated values would be roughly 44.7% for  $C_{max}$  and 44.9% for AUC.

For various assumptions for the gCV, Table [7.7.1](#) provides an overview of the achievable precision for estimating the ratio of geometric means (test/reference). For illustrative purposes, the expected 90% confidence intervals are displayed for different values of the ratios T/R of geometric means.

Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies

Table 7.7: 1

Precision that can be expected with 95% probability and illustrative two-sided 90% confidence intervals around the ratios of geometric means (T/R) for different gCVs in a one-way crossover trial ( $N=12$ )

gCV [%]	Precision upper CL / relative BA estimate	Ratio [%] <sup>*</sup>	Lower CL [%]	Upper CL [%]
30.0	1.334	100	74.99	133.36
30.0	1.334	150	112.48	200.03
30.0	1.334	200	149.98	266.71
40.0	1.459	100	68.54	145.90
40.0	1.459	150	102.81	218.85
40.0	1.459	200	137.08	291.80
50.0	1.589	100	62.93	158.91
50.0	1.589	150	94.39	238.37
50.0	1.589	200	125.85	317.83

<sup>\*</sup>Ratio of geometric means (test/reference) for a PK endpoint is defined by  $\exp(\mu_T)/\exp(\mu_R)$ .

The expected 90% confidence interval limits in the table were derived by

$$\text{CI limit}_{\text{upper},\text{lower}} = \exp(\ln(\theta) \pm \omega),$$

with  $\theta$  being the ratio (T/R) on original scale and  $\omega$  the distance from the estimate  $\theta$  to either confidence interval limit on the log-scale, which was obtained from the achievable precision on the original scale.

The calculation was performed as described by Julius ([R11-5230](#)) using R Version 3.4.2.

## **8. INFORMED CONSENT, TRIAL RECORDS, DATA PROTECTION, PUBLICATION POLICY, AND ADMINISTRATIVE STRUCTURE**

The trial will be carried out in compliance with the protocol, the ethical principles laid down in the Declaration of Helsinki, in accordance with the ICH Harmonized Guideline for Good Clinical Practice (GCP), relevant BI Standard Operating Procedures (SOPs), the EU regulation 536/2014, and other relevant regulations. Investigators and site staff must adhere to these principles.

Standard medical care (prophylactic, diagnostic, and therapeutic procedures) remains the responsibility of the subject's treating physician.

The investigator will inform the sponsor immediately of any urgent safety measures taken to protect the trial subjects against any immediate hazard, as well as of any serious breaches of the protocol or of ICH GCP.

The Boehringer Ingelheim transparency and publication policy can be found on the following web page: [trials.boehringer-ingelheim.com](http://trials.boehringer-ingelheim.com). As a general rule, no trial results should be published prior to archiving of the CTR.

The terms and conditions of the insurance coverage are made available to the investigator and the subjects, and are stored in the ISF.

### **8.1 TRIAL APPROVAL, SUBJECT INFORMATION, INFORMED CONSENT**

This trial will be initiated only after all required legal documentation has been reviewed and approved by the respective Institutional Review Board (IRB) / Independent Ethics Committee (IEC) and competent authority (CA) according to national and international regulations. The same applies for the implementation of changes introduced by amendments.

Prior to a subject's participation in the trial, written informed consent must be obtained from each subject (or the subject's legally accepted representative) according to ICH-GCP and to the regulatory and legal requirements of the participating country. Each signature must be personally dated by each signatory and the informed consent and any additional subject-information form retained by the investigator as part of the trial records. A signed copy of the informed consent and any additional subject information must be given to each subject or the subject's legally accepted representative.

The subject must be given sufficient time to consider participation in the trial. The investigator or delegate obtains written consent of the subject's own free will with the informed consent form after confirming that the subject understands the contents. The investigator or delegate must sign (or place a seal on) and date the informed consent form. If a trial collaborator has given a supplementary explanation, the trial collaborator also signs (or places a seal on) and dates the informed consent.

Re-consenting may become necessary when new relevant information becomes available and should be conducted according to the sponsor's instructions.

The consent and re-consenting process should be properly documented in the source documentation.

## **8.2 DATA QUALITY ASSURANCE**

A risk-based approach is used for trial quality management. It is initiated by the assessment of critical data and processes for trial subject protection and reliability of the results as well as identification and assessment of associated risks. An Integrated Quality and Risk Management Plan documents the rationale and strategies for risk management during trial conduct including monitoring approaches, vendor management and other processes focusing on areas of greatest risk.

Continuous risk review and assessment may lead to adjustments in trial conduct, trial design or monitoring approaches.

A quality assurance audit/inspection of this trial may be conducted by the sponsor, sponsor's designees, or by IRB / IEC or by regulatory authorities. The quality assurance auditor will have access to all medical records, the investigator's trial-related files and correspondence, and the informed consent documentation of this clinical trial.

## **8.3 RECORDS**

CRFs for individual subjects will be provided by the sponsor. drug accountability, refer to Section [4.1.8](#).

ClinBase<sup>TM</sup>

In the Human Pharmacology Centre (HPC) – Boehringer Ingelheim's Phase I unit – the validated ClinBase<sup>TM</sup> system is used for processing information and controlling data collected in clinical studies. In addition to its function as a procedure control system, ClinBase<sup>TM</sup> serves as data base. Instead of being entered into CRFs, selected data are directly entered into the system.

### **8.3.1 Source documents**

In accordance with regulatory requirements, the investigator should prepare and maintain adequate and accurate source documents and trial records for each trial subject that include all observations and other data pertinent to the investigation. Source data as well as reported data should follow the 'ALCOA principles' and be attributable, legible, contemporaneous, original, and accurate. Changes to the data should be traceable (audit trail).

Data reported on the CRF must be consistent with the source data or the discrepancies must be explained.

Before providing any copy of subjects' source documents to the sponsor, the investigator must ensure that all subject identifiers (e.g., subject's name, initials, address, phone number, and social security number) have properly been removed or redacted to ensure subject confidentiality.

If the subject is not compliant with the protocol, any corrective action (e.g. re-training) must be documented in the subject file.

For the CRF, data must be derived from source documents, for example:

Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies

- Subject identification: sex, year of birth (in accordance with local laws and regulations)
- Subject participation in the trial (substance, trial number, subject number, date subject was informed)
- Dates of subject's visits, including dispensing of trial medication
- Medical history (including trial indication and concomitant diseases, if applicable)
- Medication history
- AEs and outcome events (onset date [mandatory], and end date [if available])
- SAEs (onset date [mandatory], and end date [if available])
- Concomitant therapy (start date, changes)
- Originals or copies of laboratory results and other imaging or testing results, with proper documented medical evaluation (in validated electronic format, if available)
- ECG results (original or copies of printouts)
- Completion of subject's participation in the trial (end date; in case of premature discontinuation, document the reason for it, if known)
- Prior to allocation of a subject to a treatment into a clinical trial, there must be documented evidence in the source data (e.g. medical records) that the trial participant meets all inclusion criteria and does not meet any exclusion criteria. The absence of records (either medical records, verbal documented feedback of the subject or testing conducted specific for a protocol) to support inclusion/exclusion criteria does not make the subject eligible for the clinical trial.

Data directly entered into ClinBase<sup>TM</sup> (that is, without prior written or electronic record) are considered to be source data. The place where data are entered first will be defined in a trial specific Source Data Agreement. The data in ClinBase<sup>TM</sup> are available for inspection at any time.

### **8.3.2 Direct access to source data and documents**

The investigator /institution will allow site trial-related monitoring, audits, IRB / IEC review and regulatory inspections. Direct access must be provided to the CRF and all source documents/data, including progress notes, copies of laboratory and medical test results, which must be available at all times for review by the Clinical Research Associate, auditor and regulatory inspector (e.g. FDA). They may review all CRFs and informed consents. The accuracy of the data will be verified by direct comparison with the source documents described in Section [8.3.1](#). The sponsor will also monitor compliance with the protocol and GCP.

### **8.3.3 Storage period of records**

#### **Trial site:**

The trial site(s) must retain the source and essential documents (including ISF) according to the local requirements valid at the time of the end of the trial.

**Sponsor:**

The sponsor must retain the essential documents according to the sponsor's SOPs.

#### **8.4 EXPEDITED REPORTING OF ADVERSE EVENTS**

BI is responsible to fulfil their legal and regulatory reporting obligation in accordance with regulatory requirements.

#### **8.5 STATEMENT OF CONFIDENTIALITY AND SUBJECT PRIVACY**

Individual subject data obtained as a result of this trial is considered confidential and disclosure to third parties is prohibited with the exceptions noted in Section [8.7](#).

Data protection and data security measures are implemented for the collection, storage and processing of patient data in accordance with the principles 6 and 12 of the WHO GCP handbook.

Personalised treatment data may be given to the subject's personal physician or to other appropriate medical personnel responsible for the subject's welfare. Data generated at the site as a result of the trial need to be available for inspection on request by the participating physicians, the sponsor's representatives, by the IRB / IEC and the regulatory authorities.

##### **8.5.1 Collection, storage and future use of biological samples and corresponding data**

Measures are in place to comply with the applicable rules for the collection, storage and future use of biological samples and clinical data, in particular

- Sample and data usage has to be in accordance with the informed consent
- The BI-internal facilities storing biological samples from clinical trial participants as well as the external storage facility are qualified for the storage of biological samples collected in clinical trials.
- An appropriate sample and data management system, incl. audit trail for clinical data and samples to identify and destroy such samples according to ICF is in place
- A fit for the purpose documentation (biomarker proposal, analysis plan and report) ensures compliant usage
- A fit for purpose approach will be used for assay/equipment validation depending on the intended use of the biomarker data

Samples and/or data may be transferred to third parties and other countries as specified in the ICF.

#### **8.6 TRIAL MILESTONES**

The **start of the trial** is defined as the date of the enrolment of the first subject in the trial.

The **end of the trial** is defined as the 'date of the last visit of the last subject in whole trial' ('Last Subject Completed') or 'end date of the last open AE' or 'date of the last follow-up test' or 'date of an AE has been decided as sufficiently followed-up', whichever is latest.

Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies

**Early termination of the trial** is defined as the premature termination of the trial for any reason before the end of the trial as specified in this protocol.

**Temporary halt of the trial** is defined as any unplanned interruption of the trial by the sponsor with the intention to resume it.

**Suspension of the trial** is defined as an interruption of the trial based on a Health Authority request.

The EC/competent authority in each participating EU member state will be notified about the trial milestones according to the laws of each member state.

A final report of the clinical trial data will be written only after all subjects have completed the trial in all countries (EU or non-EU), so that all data can be incorporated and considered in the report.

The sponsor will submit to the EU database a summary of the final trial results within one year from the end of a clinical trial as a whole, regardless of the country of the last patient (EU or non-EU).

## **8.7 ADMINISTRATIVE STRUCTURE OF THE TRIAL**

The trial is sponsored by Boehringer Ingelheim (BI).

The trial will be conducted at the

, under the supervision of the Principal Investigator. Relevant documentation on the participating (Principal) Investigators (e.g. their curricula vitae) will be filed in the ISF.

BI has appointed a Clinical Trial Leader, responsible for coordinating all required trial activities, in order to

- Manage the trial in accordance with applicable regulations and internal SOPs
- Direct the clinical trial team in the preparation, conduct, and reporting of the trial
- ensure appropriate training and information of Clinical Trial Managers, Clinical Research Associates, and investigators of participating trial sites

The trial medication will be provided by the Clinical Trial Supplies Unit, BI Pharma GmbH & Co. KG, Biberach, Germany (BI 1323495) or will be obtained by the clinical trial site from public pharmacy (itraconazole).

Safety laboratory tests will be performed by the local laboratory of the trial site

Analyses of BI 1323495 concentrations in plasma will be performed at the Department of Drug Metabolism and Pharmacokinetics Germany, BI Pharma GmbH & Co. KG, Biberach, Germany.

Analyses of itraconazole concentrations in plasma will be performed at

On-site monitoring will be performed by BI or a contract research organisation appointed by BI.

Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies

Data management and statistical evaluation will be done by BI or a contract research organisation appointed by BI according to BI SOPs.

Tasks and functions assigned in order to organise, manage, and evaluate the trial are defined according to BI SOPs. A list of responsible persons and relevant local information can be found in the ISF.

## **9. REFERENCES**

### **9.1 PUBLISHED REFERENCES**

P07-13746 Heeswijk RPG van, Bourbeau M, Campbell P, Seguin I, Chauhan BM, Foster BC, Cameron DW. Time-dependent interaction between lopinavir/ritonavir and fexofenadine. *J Clin Pharmacol* 46, 758-767 (2006).

P15-06298 Ministry of Health, Labour and Welfare. Drug interaction guideline for drug development and labeling recommendations (draft). [http://www.solvobiotech.com/documents/Japanese\\_DDI\\_guideline\\_\(draft\)\\_2014Jan.pdf](http://www.solvobiotech.com/documents/Japanese_DDI_guideline_(draft)_2014Jan.pdf) (access date: 22 June 2015); Ministry of Health, Labour and Welfare; 2014.

P15-06991 European Medicines Agency (EMA). Committee for Human Medicinal Products (CHMP): guideline on the investigation of drug interactions (21 June 2012, CPMP/EWP/560/95/rev. 1 corr. 2). [http://www.ema.europa.eu/docs/en\\_GB/document\\_library/Scientific\\_guideline/2012/07/WC500129606.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/07/WC500129606.pdf) (access date: 8 July 2015); London: European Medicines Agency (EMA); 2012.

P17-01597 Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease (2017 report). <http://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-co-pd/> (access date: 9 February 2017); Global Initiative for Chronic Obstructive Lung Disease (GOLD); 2017.

R01-0516 Olkkola KT, Backman JT, Neuvonen PJ. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. *Clin Pharmacol Ther* 1994. 55(5):481-485.

R08-1652 Kharasch ED, Bedynek PS, Walker A, Whittington D, Hoffer C. Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities. *Clinical Pharmacology and Therapeutics, advance online publication* 9 July 2008, doi:10.1038/clpt.2008.102 *Clin Pharmacol Ther* 2008.

R10-1102 Templeton IE, Thummel KE, Kharasch ED, Kunze KL, Hoffer C, Nelson WL, Isoherranen N. Contribution of itraconazole metabolites to inhibition of CYP3A4 in vivo. *Clin Pharmacol Ther* 2008; 83(1):77-85. *Clin Pharmacol Ther* 1994. 55(5):481-485.

R11-5230 Julious SA. Sample sizes for clinical trials. Boca Raton: Taylor & Francis Group; 2010.

Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies

R12-1392 Levey AS, Stevens LA, Schmid CH, Zhang Y, Castro AF, Feldman HI, Kusek JW, Eggers P, Lente F van, Greene T, Coresh J, Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI). A new equation to estimate glomerular filtration rate. *Ann Intern Med* 2009; 150(9):604-612.

R15-3252 Jalava KM, Partanen J, Neuvonen PJ. Itraconazole decreases renal clearance of digoxin. *Ther Drug Monit* 1997. 19(6):609-613.

R17-3742 Barone JA, Moskovitz BL, Guarneri J, Hassell AE, Colaizzi JL, Bierman RH, et al. Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers. *Pharmacotherapy* 1998; 18(2):295-301.

R17-3743 Willems L, Geest R van der, Beule K de. Itraconazole oral solution and intravenous formulations: a review of pharmacokinetics and pharmacodynamics. *J Clin Pharm Ther* 2001; 26:159-169.

R17-3744 Liu L, Bello A, Dresser MJ, Heald D, Komjathy SF, O'Mara E, et al. Best practices for the use of itraconazole as a replacement for ketoconazole in drug-drug interaction studies. *J Clin Pharmacol* 2016. 56(2):143-151.

R18-0241 Guidance for industry: clinical drug interaction studies - study design, data analysis, and clinical implications (draft guidance, this guidance document is being distributed for comment purposes only) (October 2017, clinical pharmacology).  
<https://www.fda.gov/downloads/drugs/guidances/ucm292362.pdf> (access date: 19 January 2018); Silver Spring: U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) 2017.

Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies

R18-2643 Sporanox 10 mg/ml oral solution (Janssen-Cilag) (summary of product characteristics, updated 01-Mar-2018). <https://www.medicines.org.uk/emc/product/1522/smpc/print> (access date: 14 August 2018); 2018.

R18-2644 Sempera Liquid 10 mg/ml, Lösung zum Einnehmen (Janssen-Cilag) (Fachinformation, Stand der Information: Dezember 2017). 2017.

R94-1529 Chow SC, Liu JP, editors. Design and analysis of bioavailability and bioequivalence studies. New York: Marcel Dekker Inc., 1992.

## **9.2 UNPUBLISHED REFERENCES**

001-MCS-36-472 Standards and processes for analyses performed within Clinical Pharmacokinetics/Pharmacodynamics. Current version.

c02336088 Relative bioavailability of a single oral dose of BI 691751 when administered alone or in combination with multiple oral doses of itraconazole in healthy male subjects (an open-label, randomised, two-period, two-sequence crossover study). 1334.10. 09 Jan 2015.

c03355329 Relative bioavailability of a single oral dose of BI 425809 when administered alone or in combination with multiple oral doses of itraconazole in healthy male subjects (an open-label, two-period, fixed-sequence trial). 1346.10. 03 Dec 2015.

c08928447 , Effect of multiple doses of itraconazole on the pharmacokinetics of a single oral dose of BI 1026706 in healthy male subjects (an open-label, randomised, two-period, two-sequence crossover study). 1320.20. 29 Sep 2016.

c21238478 Investigator's Brochure BI 1323495. COPD. 18 Mar 2019.

Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies

## **10. APPENDICES**

Not applicable.

Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies

## **11. DESCRIPTION OF GLOBAL AMENDMENT(S)**

### **11.1 GLOBAL AMENDMENT 1**

<b>Date of amendment</b>	18 June 2019	
<b>EudraCT number</b>	2019-001570-28	
<b>EU number</b>		
<b>BI Trial number</b>	1405-0009	
<b>BI Investigational Medicinal Product(s)</b>	BI 1323495	
<b>Title of protocol</b>	Relative bioavailability of a single oral dose of BI 1323495 when administered alone or in combination with multiple oral doses of itraconazole in healthy male subjects (an open-label, one-way crossover study)	
<b>To be implemented only after approval of the IRB / IEC / Competent Authorities</b>		<input checked="" type="checkbox"/>
<b>To be implemented immediately in order to eliminate hazard – IRB / IEC / Competent Authority to be notified of change with request for approval</b>		<input type="checkbox"/>
<b>Can be implemented without IRB / IEC / Competent Authority approval as changes involve logistical or administrative aspects only</b>		<input type="checkbox"/>
<b>Section to be changed</b>	<ol style="list-style-type: none"><li>1. Flow Chart</li><li>2. 1.4.2.5 Safety measures</li><li>3. 3.3.3 Exclusion criteria</li><li>4. 3.3.4.1 Discontinuation of trial treatment</li><li>5. 3.3.4.3 Discontinuation of the trial by the sponsor</li><li>6. 6.2.2 Treatment periods</li></ol>	
<b>Description of change</b>	<ol style="list-style-type: none"><li>1. Inhouse stay in treatment period 2 extended to 34 h</li><li>2. Period of inhouse stay amended</li><li>3. Blood coagulation disorder in exclusion criterion no. 5 added</li><li>4. Insertion of an additional criterion for discontinuation of an individual subject</li><li>5. Trial termination criterion no. 2 rephrased</li><li>6. Period of inhouse stay amended</li></ol>	
<b>Rationale for change</b>	<ol style="list-style-type: none"><li>1. Health authority/EC request</li><li>2. Health authority/EC request</li><li>3. Health authority/EC request</li><li>4. Health authority/EC request</li><li>5. Health authority/EC request</li><li>6. Health authority/EC request</li></ol>	



## APPROVAL / SIGNATURE PAGE

**Document Number:** c26556329

**Technical Version Number:** 2.0

**Document Name:** clinical-trial-protocol-version-2

**Title:** Relative bioavailability of a single oral dose of BI 1323495 when administered alone or in combination with multiple oral doses of itraconazole in healthy male subjects (an open-label, one-way crossover study)

### Signatures (obtained electronically)

Meaning of Signature	Signed by	Date Signed
Author-Clinical Trial Leader		18 Jun 2019 10:27 CEST
Approval-Team Member Medicine		18 Jun 2019 10:39 CEST
Author-Trial Statistician		18 Jun 2019 11:04 CEST
Approval-Therapeutic Area		18 Jun 2019 11:53 CEST
Verification-Paper Signature Completion		19 Jun 2019 08:01 CEST
Author-Trial Clinical Pharmacokineticist		26 Jun 2019 15:29 CEST

(Continued) Signatures (obtained electronically)

<b>Meaning of Signature</b>	<b>Signed by</b>	<b>Date Signed</b>